Medical Devices Containing Rhenium Metal Alloys

JP2024529974A5Inactive Publication Date: 2024-11-20MILLS LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024505222
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-07-28
Filing Date
2022-01-27
Publication Date
2024-11-20
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Conventional metal alloys used in medical devices, such as stainless steel and cobalt-chromium alloys, face issues with recoil during compression and expansion, limited minimum compressed diameter, damage to blood vessels, and ion release, which affect the stability and effectiveness of cardiovascular devices.

Method used

Medical devices partially or fully made of rhenium metal alloys, which include compositions like Re, Mo, Nb, Ta, Ti, V, Cr, Mn, Zr, Ru, Rh, Hf, Os, Cu, and Ir, offering improved strength, durability, and reduced recoil, while maintaining a smaller profile and minimizing ion release.

Benefits of technology

Rhenium metal alloys enhance the radial strength, reduce recoil, and improve biostability, allowing for smaller, more durable medical devices with better fit and reduced tissue irritation, maintaining shape and reducing ion release.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A medical device formed at least in part from a rhenium metal alloy.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] (cross reference) This disclosure claims priority to U.S. Provisional Application No. 63 / 226,270, filed July 28, 2021, and is incorporated herein by reference.

[0002] (Technical field) FIELD OF THE DISCLOSURE This disclosure relates generally to medical devices and medical device applications, and more particularly to medical devices formed at least in part from biomedical materials. [Background technology]

[0003] Stainless steels, cobalt-chromium alloys, and TiAlV alloys are some of the common metal alloys used in medical devices. Although these alloys have been successfully used to form a variety of medical devices, they do have some drawbacks.

[0004] Many cardiovascular devices, such as stents, expandable heart valves, etc., are inserted into a patient's body via the patient's vascular system and expanded at a treatment site. These devices are typically compressed into a catheter prior to insertion into a patient. This sets limits on the size of the cardiovascular passageway (e.g., blood vessel) into which the cardiovascular device can be inserted. A smaller compressed diameter may reduce damage to blood vessels and / or organs (e.g., heart, etc.) during insertion and / or placement of the cardiovascular device at a treatment site. A smaller compressed diameter also allows the cardiovascular device to be placed in smaller diameter blood vessels (e.g., blood vessels located in the brain, etc.).

[0005] The compressed diameter of an expandable cardiovascular device can be reduced by reducing the thickness and / or size of the cardiovascular device frame, struts, etc. However, such a reduction in size also impacts the strength of the cardiovascular device after expansion. The cardiovascular device must maintain its expanded shape in the treatment area after expansion; otherwise, the cardiovascular device may become dislodged from, damage, or not function properly in the treatment area. As such, cardiovascular devices formed from traditional materials such as stainless steels (e.g., 316L: 17-19% by weight chromium, 13-15% by weight nickel, 2-4% by weight molybdenum, up to 2% by weight manganese, up to 0.75% by weight silicon, up to 0.03% by weight carbon, balance iron) and cobalt-chromium alloys (e.g., MP35N: 19-21% by weight chromium, 34-36% by weight nickel, 9-11% by weight molybdenum, up to 1% by weight iron, up to 1% by weight titanium, up to 0.15% by weight manganese, up to 0.15% by weight silver, up to 0.025% by weight carbon, balance cobalt) must maintain a frame and / or strut size / thickness that limits how small a compressed diameter can be achieved by the compressed cardiovascular device. Other types of cobalt-chromium alloys in use are the Phynox and Elgiloy alloys (38-42% by weight cobalt, 18-22% chromium, 14-18% iron, 13-17% nickel, 6-8% molybdenum) and the L605 alloy (18-22% by weight chromium, 14-16% tungsten, 9-11% nickel, balance cobalt).

[0006] Also, conventional materials such as stainless steel (316L) and cobalt chromium alloys (e.g., MP35N) have some recoil after compression and expansion. This may prevent obtaining a minimum compressed diameter and / or may adversely affect the placement of the expandable cardiovascular device at the treatment area. In the compression process, a compression device is typically used to compress the cardiovascular device onto the catheter. After the initial compression process, it rebounds to a diameter 9+% larger than the minimum compressed diameter. Therefore, the cardiovascular device needs to be compressed onto the catheter multiple times to obtain a smaller compressed diameter of the catheter. However, subjecting the cardiovascular device to multiple compressions may cause damage to the cardiovascular device (e.g., damage to the frame and / or struts of the cardiovascular device, damage to the leaflets of the expandable heart valve, etc.). Similarly, conventional materials of cardiovascular devices rebound 9+% of their maximum expanded diameter when the cardiovascular device is expanded at the treatment area. Therefore, to ensure proper expansion of the cardiovascular device, it is necessary to repeatedly expand the cardiovascular device at the treatment area by pressurizing the inflatable balloon on the catheter multiple times. However, multiple balloon expansions of a cardiovascular device can result in damage to the cardiovascular device (e.g., damage or breakage of the frame and / or struts) and / or damage to the treatment area (e.g., rupture of a blood vessel, laceration and / or puncture of tissue of an organ, etc.).

[0007] When a medical device is inserted into a patient, it is typically desirable for the medical device to resist ionization and / or corrosion while in the patient's body so as not to be exposed to metal ions and / or oxides from the metals used to form the medical device while in the patient's body. Excessive ion release from the medical device can have adverse effects on the patient. While traditional materials such as stainless steel (316L) and cobalt-chromium alloys (such as MP35N) are very stable when inserted into a patient, some metal ion release occurs while the medical device is in the patient's body.

[0008] Given the current state of the art in medical devices, there is a need for improved medical devices that a) have reduced recoil compared to medical devices formed from stainless steel, cobalt-chromium alloys, or TiAlV alloys; b) are capable of forming smaller compressed diameters compared to medical devices formed from stainless steel, cobalt-chromium alloys, or TiAlV alloys; and / or c) have reduced release of metal ions compared to medical devices formed from stainless steel, cobalt-chromium alloys, or TiAlV alloys. Summary of the Invention [Means for solving the problem]

[0009] The present disclosure relates to medical devices made at least in part from rhenium metal alloys, including orthopedic devices, PFO (patent foramen ovale) devices, stents, valves (e.g., heart valves, TAVR valves, mitral valve replacements, tricuspid valve replacements, pulmonary valve replacements, etc.), spinal implants, frames and other structures for use with spinal implants, vascular implants, grafts, guidewires, sheaths, catheters, needles, stent catheters, electrophysiology catheters, hypotubes, staples, cutting devices, implants of any kind, pacemakers, dental implants, dental crowns, orthodontic appliances, wires used in medical procedures, bone implants, artificial intervertebral discs, artificial spinal discs, prosthetic implants, or bone (e.g., acromion, The present invention may include devices, bone plates nails, rods, screws, posts, cages, plates, pedicle screws, caps, hinges, joint systems, anchors, spacers, shafts, anchors, disks, balls, tension bands, locking connectors, mounts, and / or other structural assemblies for use in repairing, replacing, and / or supporting structures within the body, such as, but not limited to, the atlas, axis, calcaneus, carpals, clavicle, coccyx, epicondyle, supraspinatus, femur, fibula, frontal bone, greater trochanter, humerus, ilium, ischium, mandible, maxilla, metacarpals, metatarsals, occipital bone, olecranon, parietal bone, patella, phalanges, radius, ribs, sacrum, scapula, sternum, talus, tarsus, temporal bone, tibia, ulna, zygomatic bone, etc.) and / or cartilage. In one non-limiting embodiment, the medical device comprises an expandable frame (e.g., a stent, a prosthetic heart valve, etc.) that can be plastically deformed radially outwardly by an expansion mechanism (e.g., an inflatable balloon, etc.) In another non-limiting embodiment, the rhenium metal alloy is not a self-expanding alloy.

[0010] According to another and / or alternative non-limiting aspect of the present disclosure, a medical device is provided that is formed partially or completely of a rhenium metal alloy. In one non-limiting embodiment, 50-100% (and all values ​​and ranges therebetween) of the medical device is formed of a rhenium metal alloy. In another non-limiting embodiment, at least 30% by weight of the rhenium metal alloy (e.g., 30-99% by weight and all values ​​and ranges therebetween) comprises rhenium. In another non-limiting embodiment, at least 35% by weight of the rhenium metal alloy comprises rhenium. In another non-limiting embodiment, at least 35 weight percent of the rhenium metal alloy (e.g., 35 to 99.9 weight percent, and all values ​​and ranges therebetween) comprises rhenium, and 0.1 to 65 weight percent of the rhenium metal alloy (and all values ​​and ranges therebetween) comprises one or more of molybdenum, niobium, tantalum, titanium, vanadium, chromium, manganese, zirconium, technetium, ruthenium, rhodium, hafnium, osmium, copper, and / or iridium. In another non-limiting embodiment, 35-60 wt% of the rhenium metal alloy (and all values ​​and ranges therebetween) comprises rhenium, and 40-65 wt% of the rhenium metal alloy (and all values ​​and ranges therebetween) comprises one or more of molybdenum, niobium, tantalum, tungsten, titanium, vanadium, chromium, manganese, zirconium, technetium, ruthenium, rhodium, hafnium, osmium, copper, and / or iridium. In another non-limiting embodiment, 35-60 wt% of the rhenium metal alloy (e.g., and all values ​​and ranges therebetween) comprises rhenium, and 40-65 wt% of the rhenium metal alloy (and all values ​​and ranges therebetween) comprises two or more of molybdenum, niobium, tantalum, tantalum, titanium, vanadium, chromium, manganese, zirconium, technetium, ruthenium, rhodium, hafnium, osmium, copper, and / or iridium.In another non-limiting embodiment, 35-60 wt.% (e.g., and all values ​​and ranges therebetween) of the rhenium metal alloy comprises rhenium, and 40-65 wt.% (and all values ​​and ranges therebetween) of the rhenium metal alloy comprises three or more of molybdenum, niobium, tantalum, titanium, vanadium, chromium, manganese, zirconium, technetium, ruthenium, rhodium, hafnium, osmium, copper, and / or iridium.

[0011] In another non-limiting embodiment, the rhenium metal alloy contains 0-0.1 wt. % (and all values ​​and ranges therebetween) of impurities (such as metals other than rhenium, molybdenum, niobium, tantalum, titanium, vanadium, chromium, manganese, zirconium, technetium, ruthenium, rhodium, hafnium, osmium, copper, and iridium).

[0012] In another non-limiting embodiment of the present disclosure, the metal used to form the rhenium metal alloy comprises at least 35% by weight rhenium (e.g., 35-99.9% by weight, and all values ​​and ranges therebetween) and one or more alloying agents, such as, but not limited to, molybdenum, niobium, tantalum, titanium, vanadium, chromium, manganese, zirconium, technetium, ruthenium, rhodium, hafnium, osmium, copper, and / or iridium, and / or alloys of one or more of these elements. In one non-limiting formulation, the rhenium metal alloy comprises 40-99.9% by weight rhenium and one or more of molybdenum, niobium, tantalum, titanium, vanadium, chromium, manganese, zirconium, technetium, ruthenium, rhodium, hafnium, osmium, copper, and / or iridium. In one non-limiting formulation, the rhenium metal alloy includes 50-99.9 wt.% rhenium and one or more of molybdenum, niobium, tantalum, titanium, vanadium, chromium, manganese, zirconium, technetium, ruthenium, rhodium, hafnium, osmium, copper, and / or iridium.

[0013] In another non-limiting aspect of the present disclosure, the metals used to form the rhenium metal alloy include rhenium, molybdenum, and one or more alloying metals selected from the group consisting of bismuth, chromium, copper, hafnium, iridium, manganese, niobium, osmium, rhodium, ruthenium, tantalum, technetium, titanium, tungsten, vanadium, yttrium, and zirconium. In one non-limiting embodiment, the total weight percentage of rhenium and alloying metals in the rhenium metal alloy is equal to or greater than the weight percentage of molybdenum in the rhenium metal alloy. In another non-limiting embodiment, the total weight percentage of rhenium and alloying metals in the rhenium metal alloy is greater than the weight percentage of molybdenum in the rhenium metal alloy. In another non-limiting embodiment, the weight percentage of molybdenum in the rhenium metal alloy is at least 10% by weight and less than 60% by weight (and all values ​​and ranges therebetween). In another non-limiting embodiment, the weight percentage of rhenium in the rhenium metal alloy is 35-60 weight percent (and all values ​​and ranges therebetween). In another non-limiting embodiment, the total weight percentage of the alloying metals is 5-45 weight percent (and all values ​​and ranges therebetween) of the rhenium metal alloy. In another non-limiting embodiment, the weight percentage of rhenium in the rhenium metal alloy is greater than the total weight percentage of the alloying metals. In another non-limiting embodiment, the total weight percentage of rhenium, molybdenum, and one or more alloying metals in the rhenium metal alloy is at least 99.9 weight percent. In another non-limiting embodiment, the alloying metal comprises chromium. In another non-limiting embodiment, the alloying metal comprises chromium and one or more metals selected from the group consisting of bismuth, zirconium, iridium, niobium, tantalum, titanium, and yttrium. In another non-limiting embodiment, the alloying metal comprises chromium and one or more metals selected from the group consisting of bismuth, zirconium, iridium, niobium, tantalum, titanium, and yttrium, wherein the atomic ratio of chromium to the atomic ratio of each or all of the metals selected from the group consisting of bismuth, chromium, iridium, niobium, tantalum, titanium, and yttrium is from 0.4:1 to 2.5:1 (and all values ​​and ranges therebetween).In another non-limiting embodiment, the alloying metal comprises chromium and one or more metals selected from the group consisting of zirconium, niobium, and tantalum. In another non-limiting embodiment, the alloying metal comprises a first metal selected from the group consisting of bismuth, chromium, iridium, niobium, tantalum, titanium, yttrium, and zirconium, and a second metal selected from the group consisting of bismuth, chromium, iridium, niobium, tantalum, titanium, yttrium, and zirconium, wherein the first metal and the second metal are different and the atomic ratio of the first metal to the second metal is 0.4:1 to 2.5:1 (and all values ​​and ranges therebetween). In another non-limiting embodiment, the alloying metals are a first metal selected from the group consisting of chromium, niobium, tantalum, and zirconium, and a second metal selected from the group consisting of chromium, niobium, tantalum, and zirconium, wherein the first metal and the second metal are distinct from each other and the atomic ratio of the first metal to the second metal is 0.4:1 to 2.5:1 (and all values ​​and ranges therebetween).

[0014] Some non-limiting examples of rhenium metal alloys that can be produced in accordance with the present disclosure are set forth below.

[0015] [Table 1]

[0016] [Table 2]

[0017] [Table 3]

[0018] [Table 4]

[0019] [Table 5]

[0020] In Examples 1-36, all of the ranges stated above will be understood to include any value between that range and any other range between the ranges stated above. The values ​​listed above, including the symbol <, include the range from 0 to the specified value and all values ​​and ranges therebetween.

[0021] In another and / or alternative non-limiting aspect of the present disclosure, the sum of the weight percentage of rhenium and the weight percentage of the total weight percentage of bismuth, niobium, tantalum, tungsten, titanium, vanadium, chromium, manganese, yttrium, zirconium, technetium, ruthenium, rhodium, hafnium, osmium, copper and iridium is greater than the weight percentage of molybdenum in the rhenium metal alloy. In one particular non-limiting formulation, the sum of the weight percentage of rhenium and the weight percentage of the total weight percentage of bismuth, chromium, iridium, niobium, tantalum, titanium, yttrium and zirconium is greater than the weight percentage of molybdenum in the rhenium metal alloy. In another particular non-limiting formulation, the sum of the weight percentage of rhenium and the weight percentage of the total weight percentage of chromium, niobium, tantalum and zirconium is greater than the weight percentage of molybdenum in the rhenium metal alloy. In another non-limiting specific non-limiting formulation, the weight percentage of molybdenum in the rhenium metal alloy is at least 10 weight percent and less than 50 weight percent (and all values ​​and ranges therebetween). In another non-limiting specific non-limiting formulation, the weight percentage of rhenium in the rhenium metal alloy is 41-58.5 weight percent (and all values ​​and ranges therebetween), the weight percentage of molybdenum in the rhenium metal alloy is at least 15-45 weight percent (and all values ​​and ranges therebetween), and the combined weight percentage of bismuth, niobium, tantalum, tungsten, titanium, vanadium, chromium, manganese, yttrium, zirconium, technetium, ruthenium, rhodium, hafnium, osmium, copper, and iridium in the rhenium metal alloy is 11-41 weight percent (and all values ​​and ranges therebetween). In another non-limiting specific non-limiting formulation, the weight percentage of rhenium in the rhenium metal alloy is 41 to 58.5 weight percent (and all values ​​and ranges therebetween), the weight percentage of molybdenum in the rhenium metal alloy is at least 15 to 45 weight percent (and all values ​​and ranges therebetween), and the combined weight percentage of bismuth, chromium, iridium, niobium, tantalum, titanium, yttrium, and zirconium in the rhenium metal alloy is 11 to 41 weight percent (and all values ​​and ranges therebetween).In another non-limiting specific non-limiting formulation, the weight percentage of rhenium in the rhenium metal alloy is 41-58.5 weight percent (and all values ​​and ranges therebetween), the weight percentage of molybdenum in the rhenium metal alloy is at least 15-45 weight percent (and all values ​​and ranges therebetween), and the combined weight percentage of chromium, niobium, tantalum, and zirconium in the rhenium metal alloy is 11-41 weight percent (and all values ​​and ranges therebetween). In another non-limiting embodiment of the invention, the weight percentage of rhenium in the rhenium metal alloy is greater than the combined weight percentages of bismuth, chromium, iridium, niobium, tantalum, titanium, yttrium, and zirconium in the rhenium metal alloy. In another non-limiting specific non-limiting formulation, the weight percentage of rhenium in the rhenium metal alloy is greater than the combined weight percentages of chromium, niobium, tantalum, and zirconium in the rhenium metal alloy.

[0022] In another and / or alternative non-limiting aspect of the disclosure, the atomic weight ratio of rhenium to the atomic weight ratio of the combination of bismuth, niobium, tantalum, tungsten, titanium, vanadium, chromium, manganese, yttrium, zirconium, technetium, ruthenium, rhodium, hafnium, osmium, copper, and iridium is from 0.7:1 to 1.5:1 (and all values ​​and ranges therebetween), typically from 0.8:1 to 1.4:1, more typically from 0.8:1 to 1.25:1, and even more typically from about 0.9:1 to 1.1:1 (e.g., 1:1). In one particular non-limiting formulation, the atomic weight ratio of rhenium to the atomic weight ratio of the combination of bismuth, chromium, iridium, niobium, tantalum, titanium, yttrium, and zirconium is 0.7:1 to 5.1:1 (and all values ​​and ranges therebetween), typically 0.8:1 to 1.5:1, more typically 0.8:1 to 1.25:1, and even more typically about 0.9:1 to 1.1:1 (e.g., 1:1). In one particular non-limiting formulation, the atomic weight ratio of rhenium to the atomic weight ratio of the combination of chromium, niobium, tantalum, and zirconium is 0.7:1 to 5.1:1 (and all values ​​and ranges therebetween), typically 0.8:1 to 1.5:1, more typically 0.8:1 to 1.25:1, and even more typically about 0.9:1 to 1.1:1 (e.g., 1:1).

[0023] In another and / or alternative non-limiting aspect of the present disclosure, when the rhenium metal alloy comprises two of bismuth, niobium, tantalum, tungsten, titanium, vanadium, chromium, manganese, yttrium, zirconium, technetium, ruthenium, rhodium, hafnium, osmium, copper, and iridium, the atomic ratio of the two metals is 0.4:1 to 2.5:1 (and all values ​​and ranges therebetween), typically 0.5:1 to 2:1. In one particular non-limiting formulation, when the rhenium metal alloy comprises two of bismuth, chromium, iridium, niobium, tantalum, titanium, yttrium, and zirconium, the atomic ratio of the two metals is 0.4:1 to 2.5:1 (and all values ​​and ranges therebetween), typically 0.5:1 to 2:1. In another specific non-limiting formulation, when the rhenium metal alloy contains two of chromium, niobium, tantalum, and zirconium, the atomic ratio of the two metals is from 0.4:1 to 2.5:1 (and all values ​​and ranges therebetween), typically from 0.5:1 to 2:1.

[0024] In another and / or alternative non-limiting aspect of the present disclosure, the rhenium metal alloy optionally contains less than about 5 wt.% (e.g., 0-4.999999 wt.%, and all values ​​and ranges therebetween) of other metals and / or impurities, typically 0-1 wt.%, more typically 0-0.1 wt.%, even more typically 0-0.01 wt.%, and even more typically 0-0.001 wt.%. Higher purity rhenium metal alloys result in a more homogeneous alloy, which results in a more uniform density throughout the rhenium metal alloy, as well as desirable yield and ultimate tensile strengths of the rhenium metal alloy. In one particular non-limiting formulation, the rhenium metal alloy is formed from rhenium and at least two metals selected from the group consisting of molybdenum, bismuth, niobium, tantalum, tungsten, titanium, vanadium, chromium, manganese, yttrium, zirconium, technetium, ruthenium, rhodium, hafnium, osmium, copper, and iridium, and the content of the rhenium metal alloy including other elements and compounds is 0-0.1 wt.%, typically 0-0.01 wt.%, and more typically 0-0.001 wt.%. In another specific non-limiting formulation, the rhenium metal alloy is formed from rhenium and at least two metals selected from the group of molybdenum, bismuth, chromium, iridium, niobium, tantalum, titanium, yttrium, and zirconium, and the content of the rhenium metal alloy including other elements and compounds is 0 to 0.1 wt%, typically 0 to 0.01 wt%, and more typically 0 to 0.001 wt%. In another specific non-limiting formulation, the rhenium metal alloy is formed from rhenium and at least three metals selected from the group of rhenium, molybdenum, chromium, niobium, tantalum, and zirconium, and the content of the rhenium metal alloy including other elements and compounds is 0 to 0.1 wt%, typically 0 to 0.01 wt%, and more typically 0 to 0.001 wt%.

[0025] According to another and / or alternative non-limiting aspect of the present disclosure, a rhenium metal alloy that may optionally be used to partially or completely form a medical device comprises 38-60 wt. % Re, 29 wt. % to less than 50 wt. % Mo (and all values ​​and ranges therebetween), and 10-30 wt. % additional metals (and all values ​​and ranges therebetween), with the combined content of Re and Mo constituting 70-90 wt. % (and all values ​​and ranges therebetween) of the rhenium metal alloy, % (and all values ​​and ranges therebetween) of the rhenium metal alloy, the metal additive comprising one or more metals selected from the group of bismuth, niobium, tantalum, tungsten, titanium, vanadium, chromium, manganese, yttrium, zirconium, technetium, ruthenium, rhodium, hafnium, osmium, copper, and iridium, and optionally, the atomic ratio of Re is 0.8:1 to 1.25:1 (and all values ​​and ranges therebetween) relative to the total content of the additive materials in the rhenium metal alloy.

[0026] According to another and / or alternative non-limiting aspect of the present disclosure, a rhenium metal alloy that may optionally be used to partially or completely form a medical device comprises 40-55 wt. % Re (and all values ​​and ranges therebetween), 30-46 wt. % Mo (and all values ​​and ranges therebetween), and 12-20 wt. % additional metals (and all values ​​and ranges therebetween), with the combined content of Re and Mo constituting 80-88 wt. % (and all values ​​and ranges therebetween) of the rhenium metal alloy, and the sum of Re, Mo and additional metals is 12-20 wt. The total content of the metal additives constitutes 99-100% by weight of the rhenium metal alloy (and all values ​​and ranges therebetween), and the metal additives include one or more metals selected from the group of bismuth, niobium, tantalum, tungsten, titanium, vanadium, chromium, manganese, yttrium, zirconium, technetium, ruthenium, rhodium, hafnium, osmium, copper, and iridium, and optionally, the atomic ratio of Re is 0.8:1 to 1.25:1 (and all values ​​and ranges therebetween) relative to the total content of the additive materials in the rhenium metal alloy.

[0027] According to another and / or alternative non-limiting aspect of the present disclosure, a rhenium metal alloy that may optionally be used to partially or completely form a medical device comprises 38-60 wt. % Re (and all values ​​and ranges therebetween), 29 wt. % to less than 50 wt. % Mo (and all values ​​and ranges therebetween), and 10-30 wt. % additional metals (and all values ​​and ranges therebetween), where the combined content of Re and Mo constitutes 70-90 wt. % (and all values ​​and ranges therebetween) of the rhenium metal alloy, and the sum of Re, Mo and additional metals is 10-30 wt. The total content of the metal additives comprises 99-100% by weight of the rhenium metal alloy (and all values ​​and ranges therebetween), and the metal additives include chromium and, optionally, one or more metals selected from the group of bismuth, niobium, tantalum, tungsten, titanium, vanadium, manganese, yttrium, zirconium, technetium, ruthenium, rhodium, hafnium, osmium, copper, and iridium, and the atomic ratio of Re is optionally 0.8:1 to 1.25:1 (and all values ​​and ranges therebetween) relative to the total content of the additive materials in the rhenium metal alloy.

[0028] According to another and / or alternative non-limiting aspect of the present disclosure, a rhenium metal alloy that may optionally be used to partially or completely form a medical device comprises 40-55 wt. % Re (and all values ​​and ranges therebetween), 30-46 wt. % Mo (and all values ​​and ranges therebetween), and 12-20 wt. % additional metals (and all values ​​and ranges therebetween), with the combined content of Re and Mo constituting 80-88 wt. % (and all values ​​and ranges therebetween) of the rhenium metal alloy, and the combined content of Re, Mo, and additional metals is 12-20 wt. The amount of the metal additive comprises 99-100% by weight of the rhenium metal alloy (and all values ​​and ranges therebetween), the metal additive comprising chromium and one or more metals selected from the group of bismuth, niobium, tantalum, tungsten, titanium, vanadium, manganese, yttrium, zirconium, technetium, ruthenium, rhodium, hafnium, osmium, copper, and iridium, and optionally, the atomic ratio of Re is 0.8:1 to 1.25:1 (and all values ​​and ranges therebetween) relative to the total content of the additive materials in the rhenium metal alloy.

[0029] According to another and / or alternative non-limiting aspect of the present disclosure, a rhenium metal alloy that may optionally be used to partially or completely form a medical device comprises 38-60 wt. % Re (and all values ​​and ranges therebetween), 29 wt. % to less than 50 wt. % Mo (and all values ​​and ranges therebetween), and 10-30 wt. % additive metals (and all values ​​and ranges therebetween), wherein the combined content of Re and Mo constitutes 70-90 wt. % (and all values ​​and ranges therebetween) of the rhenium metal alloy, and wherein the combined content of Re, Mo and additive metals constitutes 99-100 wt. % (and all values ​​and ranges therebetween) of the rhenium metal alloy, said metal additives comprising chromium and, optionally, one or more metals selected from the group of niobium, tantalum, and zirconium, and wherein the atomic ratio of Re is optionally 0.8:1 to 1.25:1 relative to the total content of additive materials in the rhenium metal alloy.

[0030] According to another and / or alternative non-limiting aspect of the present disclosure, a rhenium metal alloy that may optionally be used to partially or completely form a medical device comprises 38-60 wt. % Re (and all values ​​and ranges therebetween), 29 wt. % to less than 50 wt. % Mo (and all values ​​and ranges therebetween), and 10-30 wt. % additional metals (and all values ​​and ranges therebetween), with the combined content of Re and Mo constituting 70-90 wt. % (and all values ​​and ranges therebetween) of the rhenium metal alloy, and the total content of Re, Mo and additional metals is 10-30 wt. The total content constitutes 99-100% by weight of the rhenium metal alloy (and all values ​​and ranges therebetween), and the metal additive comprises chromium and one or more metals selected from the group of bismuth, niobium, tantalum, tungsten, titanium, vanadium, manganese, yttrium, zirconium, technetium, ruthenium, rhodium, hafnium, osmium, copper, and iridium, and the atomic ratio of Re is optionally 0.8:1-1.25:1 (and all values ​​and ranges therebetween) relative to the total content of the additive materials in the rhenium metal alloy.

[0031] According to another and / or alternative non-limiting aspect of the present disclosure, a rhenium metal alloy that may optionally be used to partially or completely form a medical device comprises 38-60 wt. % Re (and all values ​​and ranges therebetween), 29 wt. % to less than 50 wt. % Mo (and all values ​​and ranges therebetween), and 10-30 wt. % additive metals (and all values ​​and ranges therebetween), wherein the combined content of Re and Mo constitutes 70-90 wt. % (and all values ​​and ranges therebetween) of the rhenium metal alloy, wherein the combined content of Re, Mo and additive metals constitutes 99-100 wt. % (and all values ​​and ranges therebetween) of the rhenium metal alloy, wherein the metal additives comprise chromium and one or more metals selected from the group of niobium, tantalum, and zirconium, and wherein the atomic ratio of Re is optionally 0.8:1 to 1.25:1 (and all values ​​and ranges therebetween) relative to the total content of additive materials in the rhenium metal alloy.

[0032] According to another and / or alternative non-limiting aspect of the present disclosure, a medical device (e.g., a stent, a prosthetic heart valve, etc.) is provided that is configured to be radially collapsible to a folded or compressed state for introduction into the body on a delivery catheter, and radially expandable to an expanded state for implantation of the prosthetic heart valve at a desired location within the body (e.g., blood vessel, heart, ureter, bile duct, pancreatic duct, esophagus, lung, eye, sinus, oral stent, etc.). The frame of the medical device can be formed of a plastically expandable material that allows the frame to be compressed to a smaller profile for delivery and expansion of the medical device using an expansion device such as a balloon of a balloon catheter.

[0033] According to another and / or alternative non-limiting aspect of the present disclosure, a medical device is provided that includes a frame including a plurality of angularly spaced posts, vertically extending posts or struts. The posts can be interconnected via a lower row of circumferentially extending struts and an upper row of circumferentially extending struts. The struts can be arranged in a variety of patterns (e.g., zigzag patterns, sawtooth patterns, triangular patterns, polygonal patterns, elliptical patterns, etc.). One or more of the posts and / or struts can have the same or different thicknesses and / or cross-sectional shapes and / or cross-sectional areas.

[0034] According to another and / or alternative non-limiting aspect of the present disclosure, a medical device is provided that includes a frame that can be optionally coated with a polymeric material (e.g., silicone, PTFE, ePTFE, polyurethane, polyolefin, hydrogel, biological material (e.g., pericardium or a biological polymer such as collagen, gelatin, or hyaluronic acid derivatives). The coating can be used to partially or completely encapsulate the struts on the frame and / or fill openings between the struts.

[0035] According to another and / or alternative non-limiting aspect of the present disclosure, the rhenium metal alloy used to form at least a portion of the medical device has one or more improved properties (e.g., strength, durability, hardness, biostability, bendability, coefficient of friction, radial strength, flexibility, tensile strength, tensile elongation, longitudinal elongation, stress-strain properties, reduced recoil, radiopacity, thermal sensitivity, biocompatibility, improved fatigue life, crack resistance, crack propagation resistance, reduced magnetic susceptibility, etc.), improved compliance in bending, reduced recoil, increased yield strength, improved fatigue ductility, improved durability, improved fatigue life, reduced adverse tissue reactions, reduced metal ion release, reduced corrosion, reduced allergic reactions, improved hydrophilicity, reduced toxicity, reduced thickness of metal components, improved bone integration, and / or reduced ion release into tissue. These one or more improved physical properties of the rhenium metal alloy can be achieved in a medical device without increasing the bulk, volume and / or weight of the medical device, and in some cases, these improved physical properties are obtained even when the volume, bulk and / or weight of the medical device is reduced as compared to medical devices formed at least partially from conventional stainless steel, titanium alloy, or cobalt and chromium alloy materials.

[0036] Thus, the rhenium metal alloys used to at least partially form the medical devices may: 1) increase the radiopacity of the medical device; 2) increase the radial strength of the medical device; 3) increase the yield strength and / or ultimate tensile strength of the medical device; 4) improve the stress-strain characteristics of the medical device; 5) improve the compression and / or expansion characteristics of the medical device; 6) improve the flexure and / or flexibility of the medical device; 7) improve the strength and / or durability of the medical device; 8) increase the hardness of the medical device; 9) improve the recoil characteristics of the medical device; 10) improve the biostability and / or biocompatibility characteristics of the medical device; 11) improve the fatigue resistance of the medical device; 12) prevent cracking and inhibit crack propagation in the medical device; 13) enable the production of smaller, thinner and / or lighter medical devices; 14) reduce the outer diameter of the compressed medical device; 15) increase the mechanical strength of the medical device when used and / or within a treatment area; 15) improve the ability of the medical device to conform to the shape of the treatment area as it is expanded, 16) reduce the amount of recoil of the medical device relative to the shape of the treatment area as it is expanded within the treatment area, 17) increase the yield strength of the medical device, 18) improve the fatigue ductility of the medical device, 18) improve the durability of the medical device, 19) improve the fatigue life of the medical device, 20) reduce adverse tissue reactions following implantation of the medical device, 21) reduce metal ion release following implantation of the medical device, 22) reduce corrosion of the medical device following implantation of the medical device, 23) reduce allergic reactions following implantation of the medical device, 24) improve the hydrophilicity of the medical device, 25) reduce the thickness of metal components of the medical device, 26) improve bone integration with the medical device, 27) reduce ion release from the medical device into tissue, 28) reduce the magnetic susceptibility of the medical device implanted in a patient, and / or 29) reduce toxicity of the medical device following implantation of the medical device.

[0037] The medical device may optionally be subjected to one or more manufacturing processes, including, but not limited to, expanding, laser cutting, etching, compressing, annealing, drawing, pilge ring, electroplating, electropolishing, machining, plasma coating, 3D print coating, chemical vapor deposition, chemical polishing, cleaning, pickling, ion beam deposition or implantation, sputter coating, vacuum deposition, and the like.

[0038] In another and / or alternative non-limiting aspect of the present disclosure, the rhenium metal alloy used to at least partially form the medical device optionally has a substantially uniform density throughout the rhenium metal alloy and provides the desired yield and ultimate tensile strength of the rhenium metal alloy. The density of the rhenium metal alloy is generally at least about 5 gm / cc (e.g., 5 gm / cc to 21 gm / cc, and all values ​​and ranges therebetween, such as 10 to 20 gm / cc), and typically at least about 11 to 19 gm / cc. This substantially uniform high density of the rhenium metal alloy significantly improves the radiopacity of the rhenium metal alloy.

[0039] In another and / or alternative non-limiting aspect of the present disclosure, the rhenium metal alloy optionally includes a certain amount of carbon and oxygen, but this is not required. These two elements have been found to affect the forming properties and brittleness of the rhenium metal alloy. Additionally, a controlled atomic ratio of carbon to oxygen in the rhenium metal alloy minimizes the tendency of the rhenium metal alloy to form microcracks when the rhenium metal alloy is at least partially formed into a medical device and / or during use and / or expansion of the medical device in the body. Controlling the atomic ratio of carbon to oxygen in the rhenium metal alloy allows for redistribution of oxygen in the rhenium metal alloy when the rhenium metal alloy is at least partially formed into a medical device and / or during use and / or expansion of the medical device in the body, minimizing the tendency of the rhenium metal alloy to develop microcracks. It is believed that the atomic ratio of carbon to oxygen in the rhenium metal alloy helps minimize the tendency of the rhenium metal alloy to microcrack and improves the degree of elongation of the rhenium metal alloy, both of which may affect one or more physical properties of the rhenium metal alloy that are useful or desirable for forming and / or using a medical device. The atomic ratio of carbon to oxygen can be as low as about 0.2:1 (e.g., 0.2:1 to 50:1, and all values ​​and ranges therebetween). In one non-limiting formulation, the atomic ratio of carbon to oxygen in the rhenium metal alloy is generally at least about 0.3:1. Typically, the carbon content of the rhenium metal alloy is less than about 0.1 wt. % (e.g., 0-0.0999999 wt. % and all values ​​and ranges therebetween), more typically 0-0.01 wt. %. Too much carbon content can adversely affect the physical properties of the rhenium metal alloy. Generally, the oxygen content is kept at a very low level. In one non-limiting formulation, the oxygen content is less than about 0.1 wt. % (e.g., 0-0.0999999 wt. % and all values ​​and ranges therebetween), typically 0-0.01 wt. % of the rhenium metal alloy.By tightly controlling the ratio of carbon to oxygen when the oxygen content therein exceeds a certain amount, it is believed that the rhenium metal alloy has a very low tendency to form microcracks during formation of the medical device and after the medical device is inserted into a patient. In one non-limiting configuration, when the oxygen content in the rhenium metal alloy is greater than about 100 ppm, the atomic ratio of carbon to oxygen in the rhenium metal alloy is at least about 2.5:1.

[0040] In another and / or alternative non-limiting aspect of the present disclosure, the rhenium metal alloy optionally includes a controlled amount of nitrogen, but this is not required. The inclusion of a large amount of nitrogen in the rhenium metal alloy can adversely affect the ductility of the rhenium metal alloy. This can adversely affect the elongation properties of the rhenium metal alloy. If the nitrogen content in the rhenium metal alloy is too high, the ductility of the rhenium metal alloy begins to decrease unacceptably, which can adversely affect one or more physical properties of the rhenium metal alloy that are useful or desirable for forming and / or using a medical device. In one non-limiting formulation, the rhenium metal alloy includes less than about 0.001% nitrogen by weight (e.g., 0% to 0.0009999% by weight, and all values ​​and ranges therebetween). It is believed that the nitrogen content in the rhenium metal alloy should be less than the carbon or oxygen content. In one non-limiting formulation, the atomic ratio of carbon to nitrogen is at least about 1.5:1 (e.g., 1.5:1 to 400:1, and all values ​​and ranges therebetween). In another non-limiting formulation, the atomic ratio of oxygen to nitrogen is at least about 1.2:1 (eg, from 1.2:1 to 150:1, and all values ​​and ranges therebetween).

[0041] In another and / or alternative non-limiting aspect of the present disclosure, the medical device is generally designed to include at least about 5% by weight (e.g., 5-100% by weight and all values ​​and ranges therebetween) of rhenium metal alloy. In one non-limiting embodiment of the present disclosure, the medical device includes at least about 50% by weight of rhenium metal alloy. In another non-limiting embodiment of the present disclosure, the medical device includes at least about 95% by weight of rhenium metal alloy. In one particular configuration, when the medical device includes an expandable frame, the expandable frame is formed of 50-100% by weight (and all values ​​and ranges therebetween) of rhenium metal alloy, typically 75-100% by weight of rhenium metal alloy.

[0042] In another and / or alternative non-limiting aspect of the disclosure, the rhenium metal alloy is used to form all or a portion of a medical device and 1) is optionally not clad, sprayed, plated and / or formed (e.g., cold worked, hot worked, etc.) onto another metal; or 2) is optionally not sprayed, plated, clad and / or formed with another metal or metal alloy metal onto the rhenium metal alloy.

[0043] In another and / or alternative non-limiting aspect of the present disclosure, the medical device can optionally be formed from a tube or rod of high melting point metal or can be formed into a shape that is at least 80% of the final net shape of the medical device.

[0044] In another and / or alternative non-limiting aspect of the present disclosure, the rhenium metal alloy has several physical properties that positively impact a medical device when the medical device is at least partially formed from the rhenium metal alloy of the present disclosure. In one non-limiting embodiment of the present disclosure, the average Vickers hardness of the rhenium metal alloy of the present disclosure used to at least partially form the medical device is optionally at least about 150 Vickers (e.g., 150-300 Vickers and all values ​​and ranges therebetween), typically 160-240 Vickers, although this is not required. The rhenium metal alloy of the present disclosure generally has a higher average hardness than stainless steels. In another and / or alternative non-limiting embodiment of the present disclosure, the average ultimate tensile strength of the rhenium metal alloy of the present disclosure is optionally at least about 125 ksi (e.g., 125-300 ksi and all values ​​and ranges therebetween), although this is not required. In yet another and / or alternative non-limiting embodiment of the present disclosure, the average yield strength of the rhenium metal alloy of the present disclosure is optionally, but not required to be, at least about 100 ksi (e.g., 100-275 ksi and all values ​​and ranges therebetween). In yet another and / or alternative non-limiting embodiment of the present disclosure, the average grain size of the rhenium metal alloy of the present disclosure used to at least partially form the medical device is optionally about 4 ASTM or less (e.g., 4 ASTM to 20 ASTM using ASTM E112 and all values ​​and ranges therebetween, e.g., 0.35 microns to 90 microns and all values ​​and ranges therebetween). The small grain size of the rhenium metal alloy of the present disclosure allows the medical device to have desirable elongation and ductility properties useful for enabling the formation, compression and / or expansion of the medical device.

[0045] In another and / or alternative non-limiting embodiment of the present disclosure, the average tensile elongation of the rhenium metal alloy of the present disclosure used to at least partially form the medical device is optionally at least about 25% (e.g., 25-50%, and all values ​​and ranges therebetween). A rhenium metal alloy having an average tensile elongation of at least 25% is useful in facilitating proper expansion of the medical device when placed in a treatment area of ​​the body. Medical devices that do not have an average tensile elongation of at least about 25% may be more susceptible to the formation of microcracks and / or breakage during formation, compression and / or expansion of the medical device. The unique combination of metals in the disclosed rhenium metal alloys, in combination with achieving a desired purity and composition of the alloy and a desired grain size of the rhenium metal alloy, can provide: 1) a medical device having a desired high ductility at about room temperature; 2) a medical device having a desired amount of tensile elongation; 3) a homogeneous solution or solid solution of rhenium metal alloy having high radiopacity; 4) reduction or prevention of microcrack formation and / or fracture of the disclosed rhenium metal alloy tube when sizing and / or cutting the tube to form a medical device; 5) reduction or prevention of microcrack formation and / or fracture of the medical device when the medical device is being compressed; 6) reduction or prevention of microcrack formation and / or fracture of the medical device when the medical device is being compressed; the reduction or prevention of microcrack formation and / or breakage of the medical device when bent and / or expanded within the body; 7) a medical device having a desired ultimate tensile strength and yield strength; 8) a medical device having a very thin wall thickness and still having the desired radial force needed to hold the medical device open when expanded; 9) a medical device that has less recoil when the medical device is compressed onto a delivery system and / or expanded within the body; 10) a medical device that better conforms to the shape of the treatment area within the body when the medical device is expanded within the body; 11) a medical device that exhibits improved fatigue ductility; and / or 12) a medical device with improved durability.

[0046] In another and / or alternative non-limiting aspect of the present disclosure, the rhenium metal alloy is optionally at least partially formed by a swaging process, but this is not required. In one non-limiting embodiment, the rhenium metal alloy is swaged to at least partially or completely achieve the final dimensions of one or more portions of the medical device. The swaging die can be shaped to match the final dimensions of the medical device, but this is not required. When the medical device has an undercut of a hollow structure (which is not required), a separate metal piece can be placed in the undercut to at least partially fill the gap. The separate metal piece (when used) can be designed to be later removed from the undercut, but this is not required. The swaging operation can be performed on the medical device in the area to be hardened. In the case of round or curved portions of the medical device, the swaging can be rotary. In the case of non-circular portions of the medical device, the swaging of the non-circular portions of the medical device can be performed by a non-rotating swaging die. The die can be made to oscillate radially and / or longitudinally, optionally instead of or in addition to rotating. The medical device can be swaged in multiple directions, either in a single operation or multiple operations, to achieve hardness in a desired location and / or direction of the medical device. The swaging temperature for a particular rhenium metal alloy can vary. For rhenium metal alloys, the swaging temperature can be from room temperature (RT) (e.g., 10-27°C and all values ​​and ranges therebetween) to about 400°C (e.g., 10-400°C and all values ​​and ranges therebetween) when swaging is performed in air or an oxidizing environment. When swaging is performed in a controlled neutral or non-reducing environment (e.g., an inert environment), the swaging temperature can be increased to about 1500°C (e.g., 10-1500°C and all values ​​and ranges therebetween). Swaging can be performed by repeatedly hammering the hardened area of ​​the medical device at the desired swaging temperature.In one non-limiting embodiment, during the swaging process, boron and / or nitrogen ions can bombard rhenium atoms in the rhenium metal alloy containing rhenium to form ReB2, ReN2, and / or ReN3, but this is not required. ReB2, ReN2, and / or ReN3 have been found to be superhard compounds. In one non-limiting process, metals for medical devices can be machined and formed into medical devices when the metal is in a less hardened state. Thus, the raw material can first be annealed to soften it, and then the metal can be machined into the desired shape. After forming the rhenium metal alloy, the rhenium metal alloy can be rehardened. Hardening the rhenium metal alloy of the medical device improves the wear resistance and / or shape retention of the medical device. The rhenium metal alloy of the medical device generally cannot be rehardened by annealing, and therefore requires a special rehardening process. Such rehardening can be achieved by the swaging process of the present disclosure.

[0047] In another and / or alternative non-limiting aspect of the present disclosure, the rhenium metal alloy can be optionally nitrided, but this is not required. The nitrided layer on the rhenium metal alloy can act as a lubricating surface during any drawing of the rhenium metal alloy in partially or completely forming the medical device. After the rhenium metal alloy is nitrided, it is typically washed, but this is not required. During the nitriding process, the surface of the rhenium metal alloy is modified by the presence of nitrogen. The nitriding process can be performed by gas nitriding, salt bath nitriding, or plasma nitriding. In gas nitriding, nitrogen diffuses into the surface of the rhenium metal alloy and a nitrided layer is formed. The thickness and phase composition of the resulting nitrided layer can be selected to optimize the process for the specific properties required. During gas nitriding, the rhenium metal alloy is generally nitrided in the presence of nitrogen gas or a nitrogen gas mixture (e.g., 90-99% volume % N and 1-10 volume % H, etc.) at a temperature of at least about 400° C. (e.g., 400-1000° C., and all values ​​and ranges therebetween) for at least 10 seconds. In one non-limiting nitriding process, the rhenium metal alloy is heated in the presence of nitrogen or a mixture of nitrogen and hydrogen to a temperature of at least 400°C, typically about 400-800°C (and all values ​​and ranges therebetween), for at least 10 seconds (e.g., 10 seconds to 60 minutes, and all values ​​and ranges therebetween), typically about 1-30 minutes. In salt bath nitriding, nitrogen-containing salts such as cyanide salts are used. During salt bath nitriding, the rhenium metal alloy is typically exposed to a temperature of about 520-590°C. In plasma nitriding, typically the gas used for plasma nitriding is pure nitrogen. Plasma nitriding is often performed in combination with a physical vapor deposition (PVD) process, although this is not required. Plasma nitriding occurs at a temperature of typically 220-630°C (and all values ​​and ranges therebetween). The rhenium metal alloy can be optionally exposed to argon and / or hydrogen gas prior to the nitriding process to clean and / or preheat the rhenium metal alloy. These gases can optionally be used to remove oxide layers and / or solvents from the surface of the rhenium metal alloy. During the nitriding process, the rhenium metal alloy can optionally be exposed to hydrogen gas to reduce or prevent the formation of oxides on the surface of the rhenium metal alloy.The thickness of the nitrided surface layer is less than about 1 mm. In one non-limiting embodiment, the thickness of the nitrided surface layer is at least about 50 nanometers and less than about 1 mm (and all values ​​and ranges therebetween). In another non-limiting embodiment, the thickness of the nitrided surface layer is at least about 50 nanometers and less than about 0.1 mm. Generally, the weight percentage of nitrogen in the nitrided surface layer is 0.0001-5 weight percent nitrogen (and all values ​​and ranges therebetween). In one non-limiting embodiment, the weight percentage of nitrogen in the nitrided surface layer is generally less than one of the major components of the rhenium metal alloy, and typically less than each of the two major components of the rhenium metal alloy. For example, when a rhenium metal alloy is nitrided, the weight percentage of nitrogen in the nitrided surface layer is less than the weight percentage of rhenium in the nitrided surface layer. In a non-limiting composition of the nitrided surface layer on the rhenium metal alloy (e.g., 47-55 wt.% rhenium, 10-46 wt.% molybdenum, 0.1-30 wt.% additional metal alloying agent), the nitrided surface layer comprises at least 40 wt.% rhenium, at least 8 wt.% molybdenum, and 0.0001-5 wt.% nitrogen (and all values ​​and ranges therebetween). In one non-limiting embodiment of the present disclosure, the surface of the rhenium metal alloy is nitrided prior to at least one drawing step of the rhenium metal alloy. In another non-limiting aspect of the present disclosure, after the rhenium metal alloy is annealed, the rhenium metal alloy is nitrided prior to drawing. In another and / or alternative non-limiting embodiment, prior to annealing the rhenium metal alloy, the rhenium metal alloy is cleaned to remove nitride compounds on the surface of the rhenium metal alloy. The nitride compounds can be removed by a variety of procedures, including, but not limited to, grit blasting, polishing, and the like. After annealing the rhenium metal alloy, the rhenium metal alloy may be nitrided again prior to one or more drawing steps, but this is not required. As can be appreciated, the entire outer surface of the rhenium metal alloy may be nitrided, or only a portion of the outer surface of the rhenium metal alloy may be nitrided. Nitriding only selected portions of the outer surface of the rhenium metal alloy may be used to obtain different surface properties of the rhenium metal alloy, but this is not required.As can be appreciated, the final formed rhenium metal alloy can include a nitrided outer surface. The nitriding process for the rhenium metal alloy can be used to increase the surface hardness and / or wear resistance of the medical device and / or to inhibit or prevent discoloration of the rhenium metal alloy (e.g., discoloration due to oxidation, etc.). For example, the nitriding process can be used to improve the wear resistance or surface wear of the articular surface of the rhenium metal alloy used in the medical device, to increase the life of the medical device, and / or to increase the wear life of the articulating surface of the medical device (e.g., polyethylene liners of joint implants such as knee, hip, shoulder, etc.), and / or to reduce particle generation from use of the medical device, and / or to maintain the appearance of the rhenium metal alloy outer surface of the medical device.

[0048] In another and / or alternative non-limiting aspect of the present disclosure, the rhenium metal alloy can be optionally cleaned, polished, sterilized, nitrided, etc., immediately before or after it is partially or completely formed into the desired medical device for final processing of the rhenium metal alloy. In one non-limiting embodiment of the present disclosure, the rhenium metal alloy is electropolished. In one non-limiting aspect of this embodiment, the rhenium metal alloy is cleaned before being exposed to the polishing solution, but this is not required. The cleaning process (when used) can be performed by a variety of techniques, such as, but not limited to, 1) using a solvent (e.g., acetone, methyl alcohol, etc.) and wiping the rhenium metal alloy with a Kimwipe or other suitable towel, and / or 2) by at least partially dipping or immersing the rhenium metal alloy in a solvent and then ultrasonically cleaning the rhenium metal alloy. As can be appreciated, the rhenium metal alloy can be cleaned in other or additional ways. In another and / or alternative non-limiting aspect of this embodiment, the polishing solution can include one or more acids. In yet another and / or alternative non-limiting aspect of this embodiment, the rhenium metal alloy is rinsed with water and / or a solvent and dried to remove the polishing fluid on the rhenium metal alloy.

[0049] In another and / or alternative non-limiting aspect of the present disclosure, the use of rhenium metal alloys to partially or completely form a medical device can be used to increase the strength and / or hardness and / or durability of the medical device compared to stainless steel, chromium-cobalt alloys, or titanium alloys. Thus, less rhenium metal alloy can be used in the medical device to achieve comparable strength compared to medical devices formed of different metals. Thus, the use of rhenium metal alloys can result in smaller, less bulky medical devices without sacrificing strength and durability of the medical device. Such medical devices can have smaller profiles and therefore can be inserted into smaller areas, openings, and / or passages. The rhenium metal alloy can also increase the radial strength of the medical device. For example, the thickness of the walls of the medical device and / or the wires used to at least partially form the medical device can be reduced and achieve comparable or improved radial strength compared to thicker walled medical devices formed of stainless steel, titanium alloys, or alloys of cobalt and chromium. The stress-strain properties, bendability, and flexibility of the medical device can be improved, thereby increasing the life of the medical device. For example, the medical device may be used in areas where the medical device must be bent. The improved physical properties of the medical device with the rhenium metal alloy improve the fracture resistance of the medical device in such frequent bending environments. Additionally or alternatively, the improved bending and flexibility of the medical device through the use of the rhenium metal alloy allows the medical device to be more easily inserted into various areas of the body. The rhenium metal alloy may also reduce the degree of recoil during compression and / or expansion of the medical device. For example, the medical device better maintains its compressed shape and / or better maintains its expanded shape after expansion through the use of the rhenium metal alloy. Thus, when the medical device is mounted on the delivery device when it is compressed, the medical device better maintains its smaller profile during insertion of the medical device into various areas of the body. The medical device also better maintains its expanded profile after expansion, promoting the success of the medical device in the treatment area.In addition to improving the physical properties of medical devices through the use of rhenium metal alloys, rhenium metal alloys also have improved radiopacity compared to standard materials such as stainless steel or cobalt-chromium alloys, thereby reducing or eliminating the need for marker materials on the medical device. For example, rhenium metal alloys are believed to be at least about 10-20% more radiopaque than stainless steel or cobalt-chromium alloys.

[0050] In yet another and / or alternative non-limiting aspect of the present disclosure, the medical device may optionally contain and / or be coated with one or more agents that enhance the success of the medical device and / or therapeutic area. The term "agent" includes, but is not limited to, substances, pharmaceuticals, biologics, veterinary products, drugs, analogs or derivatives otherwise formulated and / or designed to prevent, inhibit, and / or treat one or more clinical and / or biological events and / or promote healing. Non-limiting examples of clinical events that may be addressed by one or more agents include viral, fungal and / or bacterial infections, vascular diseases and / or disorders, digestive diseases and / or disorders, reproductive diseases and / or disorders, lymphatic system diseases and / or disorders, cancer, implant rejection, pain, nausea, swelling, arthritis, bone diseases and / or disorders, organ failure, immune diseases and / or disorders, cholesterol problems, blood diseases and / or disorders, lung diseases and / or disorders, heart diseases and / or disorders, brain diseases and / or disorders, nerve pain and / or disorders, kidney diseases and / or disorders, ulcers, liver diseases and / or disorders. The therapeutic effects of the present invention include, but are not limited to, inflammatory bowel diseases and / or disorders, gallbladder diseases and / or disorders, pancreatic diseases and / or disorders, psychiatric disorders, respiratory diseases and / or disorders, glandular diseases and / or disorders, skin diseases and / or disorders, hearing diseases and / or disorders, oral diseases and / or disorders, nasal diseases and / or disorders, eye diseases and / or disorders, fatigue, genetic diseases and / or disorders, burns, scarring and / or scars, trauma, weight diseases and / or disorders, toxic diseases and / or disorders, hair loss, convulsions, muscle spasms, tissue repair, nerve repair, nerve regeneration, and / or the like. The types and / or amounts of agents included in and / or coated onto the medical device may vary. When more than one agent is included in and / or coated onto the medical device, the amounts of the two or more agents may be the same or different.The one or more agents can be coated on and / or impregnated into the medical device by a variety of mechanisms, including, but not limited to, spraying (e.g., atomized spray techniques), flame spray coating, powder deposition, dip coating, flow coating, dip spin coating, roll coating (direct and reverse), sonication, brushing, plasma deposition, deposition by evaporation, MEMS techniques, and rotational mold deposition. In another and / or alternative non-limiting embodiment of the present disclosure, the type and / or amount of agent included on, within, and / or with the medical device is generally selected for the treatment of one or more medical procedures. The amount of two or more agents used on, within, and / or with the medical device can be the same or different. The one or more agents, when used on and / or within the medical device, are optionally released in a controlled manner to provide a desired dose of the agent over a sustained period of time to the area to be treated. As can be appreciated, a controlled release of one or more agents on the medical device is not necessarily required and / or desirable. Thus, one or more agents on and / or within the medical device may be uncontrollably released from the medical device during and / or after insertion of the medical device into a treatment area. It may also be understood that one or more agents on and / or within the medical device may be controllably released from the medical device and one or more agents on and / or within the medical device may be uncontrollably released from the medical device. It may also be understood that one or more agents on and / or within one region of the medical device may be controllably released from the medical device and one or more agents on and / or within another region of the medical device may be uncontrollably released from the medical device.Thus, a medical device can be designed such that 1) all of the agents on and / or within the medical device are controllably released, 2) a portion of the agents on and / or within the medical device are controllably released, a portion of the agents on the medical device are uncontrollably released, or 3) no agents on and / or within the medical device are controllably released. A medical device can also be designed such that the release rates of one or more agents from the medical device are the same or different. A medical device can also be designed such that the release rates of one or more agents from one or more regions on the medical device are the same or different. Non-limiting configurations that can be used to control the release of one or more agents from a medical device include: 1) at least partially coating one or more agents with one or more polymers; 2) at least partially incorporating and / or at least partially encapsulating one or more agents in and / or with one or more polymers; and / or 3) inserting one or more agents into pores, passages, cavities, etc. of the medical device and at least partially coating or covering such pores, passages, cavities, etc. with one or more polymers. As can be appreciated, other or additional configurations can be used to control the release of one or more agents from a medical device. The one or more polymers, when used to at least partially control the release of one or more agents from a medical device, can be porous or non-porous. The one or more agents can be inserted and / or applied to one or more surface structures and / or microstructures on the medical device and / or can be used to at least partially form one or more surface structures and / or microstructures on the medical device. Thus, one or more agents on a medical device may: 1) be coated onto one or more surface regions of the medical device; 2) be inserted into and / or impregnated into one or more surface structures and / or microstructures, etc. of the medical device; and / or 3) form at least a part of the structure of the medical device or be included within at least a part of the structure of the medical device.When one or more agents are coated on a medical device, the one or more agents may be 1) coated directly onto one or more surfaces of the medical device, 2) mixed with one or more coating polymers or other coating materials and then at least partially coated onto one or more surfaces of the medical device, 3) at least partially coated onto a surface of another coating material that is at least partially coated onto the medical device, and / or 4) at least partially encapsulated between a) a surface or region of the medical device and one or more other coating materials, and / or b) two or more other coating materials. As can be appreciated, many other coating configurations can additionally or alternatively be used. When one or more agents are optionally inserted and / or impregnated into one or more internal structures, surface structures, and / or microstructures of the medical device, 1) one or more other coating materials can be at least partially applied onto one or more internal structures, surface structures, and / or microstructures of the medical device, and / or 2) one or more polymers can be combined with the one or more agents. Thus, the one or more agents may be 1) embedded in the structure of the medical device, 2) disposed in one or more internal structures of the medical device, 3) encapsulated between two polymeric coatings, 4) encapsulated between a base structure and a polymeric coating, 5) mixed into the basic structure of the medical device including at least one polymeric coating, or 6) included in a combination of one or more of 1, 2, 3, 4, and / or 5. Additionally or alternatively, the one or more coatings of one or more polymers on the medical device may include 1) one or more coatings of a non-porous polymer, 2) one or more coatings of a combination of one or more porous polymers and one or more non-porous polymers, 3) one or more coatings of a porous polymer, or 4) a combination of one or more of options 1, 2, and 3.

[0051] As can be appreciated, different agents can be optionally disposed within and / or between different polymer coating layers and / or on the structure of the medical device. As can also be appreciated, many other and / or additional coating combinations and / or configurations can be used. The concentration of one or more agents, the type of polymer, the type and / or shape of the internal structure of the medical device, and / or the thickness of the coating of one or more agents can be used to control the release time, release rate, and / or dosage of one or more agents, although other or additional combinations can also be used. Thus, there are many combinations of agents and polymer systems and locations on the medical device. As can also be appreciated, one or more agents can be deposited on the top surface of the medical device to provide an initial uncontrolled burst effect of one or more agents prior to 1) a controlled release of one or more agents through one or more layers of a polymer system including one or more non-porous polymers, and / or 2) an uncontrolled release of one or more agents through one or more layers of a polymer system. The one or more agents and / or polymers can be coated onto the medical device by a variety of mechanisms, including, but not limited to, spraying (e.g., atomized spray techniques), dip coating, roll coating, sonication, brushing, plasma deposition, and / or deposition by vapor deposition.

[0052] In further and / or alternative aspects of the present disclosure, various polymers can be optionally coated on the medical device and / or used to form at least a portion of the medical device. The one or more polymers can be used on the medical device for a variety of reasons, such as, but not limited to, 1) forming a portion of the medical device, 2) improving the physical properties of the medical device (e.g., improving strength, improving durability, improving biocompatibility, reducing friction, etc.), 3) forming a protective coating on one or more surface structures on the medical device, 4) at least partially forming one or more surface structures on the medical device, and / or 5) at least partially controlling the release rate of one or more agents from the medical device. As can be appreciated, the one or more polymers may have other or additional uses on the medical device. The one or more polymers may be porous, non-porous, biostable, biodegradable (i.e., resulting in dissolution, degradation, absorption, or a combination thereof in the body), and / or biocompatible. When the medical device is coated with one or more polymers, the polymers may include 1) one or more coatings of a non-porous polymer, 2) one or more coatings of a combination of one or more porous polymers and one or more non-porous polymers, 3) one or more coatings of one or more porous polymers and one or more coatings of one or more non-porous polymers, 4) one or more coatings of a porous polymer, or 5) one or more combinations of options 1, 2, 3, and 4. The thickness of the one or more polymer layers may be the same or different. When the one or more polymer layers are coated on at least a portion of the medical device, the one or more coatings may be applied by a variety of techniques, such as, but not limited to, vapor deposition and / or plasma deposition, spraying, dip coating, roll coating, sonication, atomization, brushing, and other or additional coating techniques may also be used.The one or more polymers that can be coated on and / or used to at least partially form the medical device are those that are considered to be biodegradable, bioresorbable or bioerodable, those that are considered to be biostable, and / or those that can be modified to be biodegradable and / or bioresorbable. The thickness of each polymer layer is generally at least about 0.01 μm and generally less than about 150 μm (e.g., 0.01 μm to 150 μm and all values ​​and ranges therebetween), although other thicknesses can be used. In one non-limiting embodiment, the thickness of the polymer layer and / or agent layer is about 0.02 to 75 μm, more specifically about 0.05 to 50 μm, and even more specifically about 1 to 30 μm. As can be appreciated, other thicknesses can be used.

[0053] In another and / or alternative non-limiting aspect of the present disclosure, the medical device may include and / or be coated with one or more agents, which may be the same or different in different regions of the medical device and / or have different amounts and / or concentrations in different regions of the medical device. For example, the medical device may be 1) in a configuration in which at least a portion of the medical device is coated with and / or includes one or more biological agents and at least another portion of the medical device is not coated with and / or does not include an agent, 2) in a configuration in which at least a portion of the medical device is coated with and / or includes one or more biological agents that are different from the one or more biological agents in at least another portion of the medical device, and / or 3) in a configuration in which at least a portion of the medical device is coated with and / or includes a concentration of one or more biological agents that is different from the concentration of the one or more biological agents in at least another portion of the medical device.

[0054] In further and / or alternative non-limiting aspects of the present disclosure, one or more portions of the medical device optionally 1) contain the same or different agents, 2) contain the same or different amounts of one or more agents, 3) contain the same or different polymer coatings, 4) contain the same or different coating thicknesses of the one or more polymer coatings, 5) one or more portions of the medical device controllably and / or uncontrollably release one or more agents, and / or 6) one or more portions of the medical device controllably release one or more agents and one or more portions of the medical device uncontrollably release one or more agents.

[0055] In yet another and / or alternative non-limiting aspect of the present disclosure, one or more surfaces of the medical device can be optionally treated to achieve the desired coating properties of the one or more agents and one or more polymers coated on the medical device. Such surface treatment techniques include, but are not limited to, cleaning, buffing, smoothing, nitriding, annealing, swaging, cold working, etching (chemical etching, plasma etching, etc.), and the like. As can be appreciated, other or additional surface treatment processes can be used prior to coating one or more agents and / or polymers on the surface of the medical device.

[0056] In yet another and / or alternative non-limiting aspect of the present disclosure, the medical device can optionally include a marker material that facilitates proper placement of the medical device within the body passageway. The marker material is typically designed to be visible to electromagnetic waves (e.g., x-ray, microwave, visible light, infrared, ultraviolet, etc.), sound waves (e.g., ultrasound, etc.), magnetic waves (e.g., MRI, etc.), and / or other types of electromagnetic waves (e.g., microwave, visible light, infrared, ultraviolet, etc.). The marker material can form all or part of the medical device and / or can be coated on one or more portions of the medical device (e.g., the flared portion and / or the body portion, the end of the medical device, at or near the transition between the body portion and the flared portion, etc.). The location of the marker material is at one or more locations on the medical device. The size of the one or more areas containing the marker material can be the same or different. The marker material can form ruler-like markings on the medical device spaced apart a predetermined distance from each other to facilitate positioning of the medical device within the body passageway. The marker material may be a hard or soft material. The marker material may be a biostable or biodegradable material.

[0057] In further and / or alternative non-limiting aspects of the present disclosure, the medical device or one or more regions of the medical device may optionally be constructed through the use of one or more microelectromechanical manufacturing (MEMS) techniques (e.g., micromachining, laser micromachining, micromolding, etc.), although other or additional manufacturing techniques may also be used.

[0058] The medical device can optionally include one or more surface structures (e.g., pores, channels, pits, ribs, slots, notches, bumps, teeth, needles, wells, holes, grooves, etc.) These structures can be formed at least in part by MEMS (e.g., micromachining, etc.) techniques and / or other types of techniques.

[0059] The medical device may optionally include one or more microstructures (e.g., microneedles, micropores, microcylinders, microcones, micropyramids, microtubes, microparallel hexahedrons, microprisms, microhemispheres, teeth, ribs, ridges, ratchets, hinges, zippers, cable tie-like structures, etc.) on the surface of the medical device. As defined herein, a "microstructure" is a structure having at least one dimension (e.g., average width, average diameter, average height, average length, average depth, etc.) of about 2 mm or less, typically about 1 mm or less. As can be understood, when a medical device includes one or more surface structures, 1) all of the surface structures may be microstructures, 2) all of the surface structures may be non-microstructures, or 3) some of the surface structures may be microstructures and some may be non-microstructures. Typically, the microstructures (when formed) extend from or into the outer surface by about 400 microns or less (0.01-400 microns and all values ​​and ranges therebetween), more typically less than about 300 microns, more typically about 15-250 microns, although other sizes can be used. The microstructures can be clustered together or dispersed throughout the surface of the medical device. Microstructures and / or surface structures of similar shapes and / or sizes can be used, or microstructures of different shapes and / or sizes can be used. When one or more surface structures and / or microstructures are designed to extend from the surface of the medical device, the one or more surface structures and / or microstructures can be formed at the extended location and / or can be designed to extend from the medical device during and / or after deployment of the medical device at the treatment area. The microstructures and / or surface structures can be designed to include and / or be fluidly connected to passageways, cavities, etc., although this is not required. The one or more surface structures and / or microstructures may, but need not, be used to engage and / or penetrate surrounding tissue or organs once the medical device is positioned on and / or within a patient. The one or more surface structures and / or microstructures may be used to facilitate forming and maintaining the shape of the medical device.In one non-limiting embodiment, one or more of the surface structures and / or microstructures may be at least partially formed of an agent and / or formed of a polymer. One or more of the surface structures and / or microstructures may include one or more internal passages that may include one or more materials (e.g., agents, polymers, etc.), but this is not required. One or more coatings on the medical device and / or one or more surface structures and / or microstructures may be used for a variety of purposes, such as, but not limited to, 1) increasing the binding and / or adhesion of one or more agents, adhesives, marker materials, and / or polymers to the medical device, 2) modifying the appearance or surface characteristics of the medical device, and / or 3) controlling the release rate of one or more agents. One or more microstructures and / or surface structures may be biostable, biodegradable, etc. The medical device or one or more regions of the medical device may be at least partially covered and / or filled with a protective material to at least partially protect one or more regions of the medical device and / or one or more microstructures and / or surface structures of the medical device from damage. The protective material may include one or more of the polymers already identified above. The protective material may be 1) biostable and / or biodegradable, and / or 2) porous and / or non-porous.

[0060] In yet another and / or alternative aspect of the present disclosure, the medical device may be an expandable device that can be optionally expanded by using other devices (e.g., balloons, etc.) Expandable medical devices can be made from materials that have no or substantially no shape memory properties.

[0061] In yet another and / or alternative non-limiting aspect of the present disclosure, a near-net process for frames or other metal components of medical devices is optionally provided. In one non-limiting embodiment of the present disclosure, a method is provided for powder pressing a material and applying additional cold work to increase post-sintering strength. In one non-limiting embodiment, a green part is pressed and then sintered. The sintered part is then pressed again to add cold work to increase mechanical strength into a pressed and sintered part. Generally, the temperature during pressing after the sintering process is 20-100°C (and all values ​​and ranges therebetween), typically 20-80°C, more typically 20-40°C. As defined herein, cold working occurs at a temperature of 150°C or less (e.g., 10-150°C, and all values ​​and ranges therebetween). The change in shape of the re-pressed sintered part needs to be determined so that the final part (pressed, sintered, re-pressed) meets the dimensional requirements of the final molded part. For rhenium metal alloys, a pre-press pressure of 1-300 tsi (tons per square inch) (and all values ​​and ranges therebetween) can be used, followed by a sintering process at at least 1600°C (e.g., 1600-2600°C and all values ​​and ranges therebetween), and a post-sintering press at a pressure of 1-300 tsi (and all values ​​and ranges therebetween) at a temperature of at least 20°C (e.g., 20-100°C and all values ​​and ranges therebetween, 20-40°C, etc.). Processes are also provided for increasing the mechanical strength of pressed metal parts by re-pressing the part after sintering to apply additional cold work to the material, thereby increasing its mechanical strength. Processes are also provided for powder pressing into near net or final parts using metal powders. In one non-limiting embodiment, the metal powder used to form the near net or final part comprises a minimum of 40% by weight rhenium and at least 25% by weight molybdenum, with the balance optionally comprising one or more of the following elements: tungsten, tantalum, chromium, niobium, zirconium, iridium, titanium, bismuth, and yttrium.In another non-limiting embodiment, the metal powder used to form the near net or final part includes 40-60 wt.% rhenium (and all values ​​and ranges therebetween) and two or more of the elements tungsten, tantalum, molybdenum, chromium, niobium, zirconium, iridium, titanium, bismuth, and yttrium. In another non-limiting embodiment, the metal powder used to form the near net or final part includes 40-60 wt.% rhenium (and all values ​​and ranges therebetween) and three or more of the elements tungsten, tantalum, molybdenum, chromium, niobium, zirconium, iridium, titanium, bismuth, and yttrium. In another non-limiting embodiment, the metal powder used to form the near net or final part includes 41-58.5 wt.% rhenium (and all values ​​and ranges therebetween) and 18-45 wt.% molybdenum (and all values ​​and ranges therebetween) and one or more additional elements of tantalum, chromium, niobium, zirconium, iridium, titanium, bismuth, and yttrium. In another non-limiting embodiment, the metal powder used to form the near net or final part includes 41-58.5 wt.% rhenium (and all values ​​and ranges therebetween) and 18-45 wt.% molybdenum (and all values ​​and ranges therebetween) and two or more additional elements of tantalum, chromium, niobium, zirconium, iridium, titanium, bismuth, and yttrium. In another non-limiting embodiment, the metal powder used to form the near net or final part comprises 41-58.5 weight percent rhenium (and all values ​​and ranges therebetween) and 18-45 weight percent molybdenum (and all values ​​and ranges therebetween) and one or more of the elements tantalum, chromium, niobium, and zirconium, with the total weight percentage of the one or more additional elements being 11-41 weight percent.In another non-limiting embodiment, the metal powder used to form the near net or final part comprises 41-58.5 weight percent rhenium (and all values ​​and ranges therebetween) and 18-45 weight percent molybdenum (and all values ​​and ranges therebetween) and two or more of the elements tantalum, chromium, niobium, and zirconium, with the total weight percentage of the two or more additional elements being 11-41 weight percent.

[0062] In yet another and / or alternative non-limiting aspect of the present disclosure, pressing of near-net or finished part composites is optionally provided. While the process of pressing metal to near-net of finished parts is well established, pressing composite structures formed of metal powder and polymer for the purpose of creating complex part shapes and foam-like structures is novel. Similarly, the use of pressing to impart specific biological materials to metal matrices is novel. In one non-limiting embodiment, a process is provided for creating metal parts with predefined voids, creating trabecular or foam structures composed of a mixture of metal and polymer powder, pressing the powder into a finished part or semi-finished green part, and then sintering the part under conditions where the polymer leaves the metal through a pyrolysis process of the polymer. The resulting part is related to the porosity associated with the size of the polymer particles and the homogeneity of the mixture during pressing prior to sintering. In another non-limiting embodiment, a process is provided in which a polymer residue is left on the metal substrate after pyrolysis, the polymer residue having some desired biological effect (e.g., masking the metal from the body by encapsulation, promoting cell attachment and growth). The polymer and metal powders can be made into various sizes to create multiple voids - some large to create pathways for cell growth, some small to create a rough surface to encourage cell attachment.

[0063] As can be understood, the polymer can be uniformly or non-uniformly distributed with the metal powder. For example, when the final molded part needs to have a uniform density and pore structure, the polymer material can be uniformly distributed with the metal powder before the polymer material and the metal powder are consolidated and pressed together, and then the metal powder is sintered together to form the metal component or medical device. Alternatively, when the formed metal part or medical device will have one or more channels, passages and / or voids in and / or on the exterior surface of the formed part or medical device, at least a portion of the polymer is not uniformly distributed with the metal powder, but instead is concentrated in or forms the entire area of ​​the one or more channels, passages and / or voids in and / or on the exterior surface of the molded part or medical device, such that when the polymer and metal powder are sintered, some or all of the polymer is decomposed and removed from the part or medical device, thereby forming such one or more channels, passages and / or voids on and / or in the exterior surface of the formed part or medical device. Thus, polymers can be used in combination with metal powders, followed by pressing and sintering, to form novel and customized shapes of medical devices or near net forms of medical devices. Generally, the polymer comprises about 0.1-70% by volume (and all values ​​and ranges therebetween) of the consolidated and pressed material prior to the sintering step, typically the polymer comprises about 1-60% by volume of the consolidated and pressed material prior to the sintering step, more typically the polymer comprises about 2-50% by volume of the consolidated and pressed material prior to the sintering step, and even more typically the polymer comprises about 2-45% by volume of the consolidated and pressed material prior to the sintering step. Thus, when the polymer comprises about 5% by volume of the consolidated and pressed material prior to the sintering step, and at least 99% of the polymer is degraded and removed from the part or medical device following the sintering step, the part may contain up to about 5% by volume of cavities and / or passageways within the part or medical device.

[0064] The type of polymer and the type of metal powder are not limited. The polymer and metal powder can be of various sizes to create multiple voids / passages / channels that can be used to create pathways for cell growth, to create a rough surface to promote cell attachment, to insert a biological agent into one or more of the voids / passages / channels, to insert a biological material into one or more of the voids / passages / channels, etc. In one non-limiting embodiment, the average particle size of the polymer is larger than the average particle size of the metal powder.

[0065] In another non-limiting embodiment of the present disclosure, after sintering, at least 98% by volume of the polymer is pyrolyzed and / or removed from the sintered material, typically at least 99% by volume of the polymer is pyrolyzed and / or removed from the sintered material, more typically at least 99.5% by volume of the polymer is pyrolyzed and / or removed from the sintered material, even more typically at least 99.9% by volume of the polymer is pyrolyzed and / or removed from the sintered material, and even more typically at least 99.95% by volume of the polymer is pyrolyzed and / or removed from the sintered material. The resulting part or medical device has porosity related to the size of the polymer particles and homogeneity of the mixture as pressed before sintering.

[0066] In another non-limiting aspect of the present disclosure, after the sintering process, a portion of the polymer remains in the sintered portion of the medical device. The polymer remaining in the sintered portion of the medical device can optionally have some desired biological effect (e.g., masking metal from the body by encapsulation, promoting cell attachment and growth). The remaining polymer can optionally include one or more biological agents that remain active after the sintering process. In one non-limiting embodiment, after the sintering process, about 5-97.5% by volume of the polymer (and all values ​​and ranges therebetween) is pyrolyzed and / or removed from the sintered material, typically about 10-95% by volume of the polymer is pyrolyzed and removed from the sintered material, and more typically about 10-80% by volume of the polymer is pyrolyzed and removed from the sintered material.

[0067] In further and / or alternative non-limiting aspects of the present disclosure, the rhenium metal alloy used to at least partially form the medical device is first formed into a blank, rod, tube, etc., and then finished into a final shape by one or more finishing processes. The rhenium metal alloy blank, rod, tube, etc. can be formed by a variety of techniques, such as, but not limited to, 1) melting the rhenium metal alloy and / or the metals that form the rhenium metal alloy (e.g., vacuum arc melting, etc.), and then extruding and / or casting the rhenium metal alloy into a blank, rod, tube, etc., 2) melting the rhenium metal alloy and / or the metals that form the rhenium metal alloy, forming a metal strip, and then rolling and welding the strip into a blank, rod, tube, etc., or 3) consolidating a metal powder of the rhenium metal alloy and / or the metals that form the rhenium metal alloy into a blank, rod, tube, etc. When forming the rhenium metal alloy into a blank, the shape and size of the blank are not limited. In one non-limiting process, near-net medical devices, blanks, rods, tubes, etc. can be formed from one or more ingots of metal or rhenium metal alloy. In one non-limiting process, an arc melting process (e.g., vacuum arc melting process, etc.) can be used to form near-net medical devices, blanks, rods, tubes, etc. In another non-limiting process, rhenium powder and tungsten powder, and optionally molybdenum powder, can be placed in a crucible (e.g., silica crucible, etc.) and heated by an induction melting furnace under a controlled atmosphere (e.g., vacuum environment, carbon monoxide environment, hydrogen and argon environment, helium, argon, etc.) to form near-net medical devices, blanks, rods, tubes, etc. It will be appreciated that other or additional processes can be used to form the rhenium metal alloy. In one non-limiting embodiment, the average particle size of the metal powder is less than about 230 mesh (e.g., less than 63 microns). In another and / or alternative non-limiting embodiment, the average particle size of the metal powder is about 2-63 microns, more specifically about 5-40 microns. As can be appreciated, smaller average particle sizes can be used.The purity of the metal powder should be selected so that the metal powder contains very low levels of carbon, oxygen, and nitrogen. Generally, the metal powder used to form the rhenium metal alloy has a carbon content of less than about 100 ppm, an oxygen content of less than about 50 ppm, and a nitrogen content of less than about 20 ppm. Typically, the metal powder used to form the rhenium metal alloy has a purity grade of at least 99.9, more typically at least about 99.95. The mixture of metal powders is then pressed together to form a solid solution of the rhenium metal alloy to form a near-net medical device, blank, rod, tube, or the like. Typically, pressing is performed by an isostatic process (i.e., uniform pressure is applied from all sides of the metal powder), although other processes can be used. When the metal powders are isostatically pressed together, typically cold isostatic pressing (CIP) is used to consolidate the metal powder, although this is not required. Pressing can be performed under an inert atmosphere. It can be performed under an oxygen-reducing atmosphere (e.g., hydrogen, argon and hydrogen mixture, etc.) and / or under vacuum, although this is not required. The average density of the near-net medical device, blank, rod, tube, etc. achieved by pressing the metal powders together is about 80-95% (and all values ​​and ranges therebetween) of the final average density of the near-net medical device, blank, rod, tube, etc., or about 70-96% (and all values ​​and ranges therebetween) of the minimum theoretical density of the rhenium metal alloy. A pressing pressure of at least about 300 MPa is typically used. Typically, the pressing pressure is about 400-700 MPa, although other pressures can be used. After pressing the metal powders together, the pressed metal powders are sintered at a temperature of at least 1600°C (e.g., 1600-3500°C, and all values ​​and ranges therebetween) to simultaneously partially or completely fuse the metal powders to form the near-net medical device, blank, rod, tube, etc. Sintering of the consolidated metal powders can be performed in an oxygen reducing atmosphere (e.g., helium, argon, hydrogen, a mixture of argon and hydrogen, etc.) and / or under vacuum, but this is not required.At high sintering temperatures, the high hydrogen atmosphere reduces both the amount of carbon and oxygen in the formed near-net medical device, blank, rod, tube, etc. The sintered metal powder generally has an as-sintered average density of about 90-99% of the minimum theoretical density of the rhenium metal alloy. Typically, the sintered rhenium metal alloy has a final average density of at least about 5 gm / cc, typically at least about 8.3 gm / cc, and can be up to about 16 gm / cc or more, although this is not required. The density of the formed near-net medical device, blank, rod, tube, etc. generally depends on the type of rhenium metal alloy used.

[0068] In further and / or alternative non-limiting aspects of the present disclosure, the near-net medical device, blank, rod, tube, etc. may be optionally cleaned and / or polished after the near-net medical device, blank, rod, tube, etc. is formed, but this is not required. Typically, the near-net medical device, blank, rod, tube, etc. is cleaned and / or polished before being further processed, but this is not required. When resizing and / or annealing of the near-net medical device, blank, rod, tube, etc. is performed, the resized and / or annealed near-net medical device, blank, rod, tube, etc. is typically cleaned and / or polished before and / or after each resizing or annealing process, or after a series of resizing and / or annealing processes, but this is not required. Cleaning and / or polishing of the near-net medical device, blank, rod, tube, etc. is used to remove impurities and / or contaminants from the surface of the near-net medical device, blank, rod, tube, etc. During processing of the near-net medical device, blank, rod, tube, etc., impurities and contaminants may be introduced into the rhenium metal alloy. The inadvertent introduction of impurities and contaminants into near-net medical devices, blanks, rods, tubes, and the like can result in undesirable amounts of carbon, nitrogen, and / or oxygen, and / or other impurities in the rhenium metal alloy. The inclusion of impurities and contaminants in the rhenium metal alloy can prematurely microcrack the rhenium metal alloy and / or adversely affect one or more physical properties of the rhenium metal alloy (e.g., reduced tensile elongation, increased ductility, increased brittleness, etc.). Cleaning of the rhenium metal alloy can be accomplished by a variety of techniques, such as, but not limited to, 1) using a solvent (e.g., acetone, methyl alcohol, etc.) and wiping the rhenium metal alloy with a Kimwipe or other suitable towel, 2) by at least partially dipping or immersing the rhenium metal alloy in a solvent and then ultrasonically cleaning the rhenium metal alloy, and / or 3) by at least partially dipping or immersing the rhenium metal alloy in an acid pickling solution.As can be appreciated, the rhenium metal alloy can be cleaned in other or additional ways. When polishing the rhenium metal alloy, the rhenium metal alloy is generally polished using a polishing solution that typically includes an acid solution, although this is not required.

[0069] In yet further and / or alternative non-limiting aspects of the present disclosure, the near-net medical device, blank, rod, tube, etc. can be resized to the desired dimensions of the medical device. In one non-limiting embodiment, the cross-sectional area or diameter of the near-net medical device, blank, rod, tube, etc. is reduced to the final near-net medical device, blank, rod, tube, etc. dimensions by a single step or series of steps. The reduction in the outer cross-sectional area or diameter of the near-net medical device, blank, rod, tube, etc. can be achieved by centerless grinding, turning, electrolytic polishing, drawing, grinding, laser cutting, shaving, polishing, electrical discharge machining, etc. The outer cross-sectional area or diameter size of the near-net medical device, blank, rod, tube, etc. can be reduced by using one or more drawing processes, but this is not required. Care must be taken to avoid the formation of microcracks in the near-net medical device, blank, rod, tube, etc. during the drawing process while reducing the outer cross-sectional area or diameter of the near-net medical device, blank, rod, tube, etc.

[0070] In further and / or alternative non-limiting aspects of the present disclosure, the near-net medical device, blank, rod, tube, etc. can optionally be, but not required to be, nitrided during the drawing process. The nitrided layer of the near-net medical device, blank, rod, tube, etc. can act as a lubricating surface during the drawing process to facilitate drawing of the near-net medical device, blank, rod, tube, etc. The near-net medical device, blank, rod, tube, etc. is typically nitrided in the presence of nitrogen or a nitrogen mixture.

[0071] In yet another and / or alternative non-limiting aspect of the present disclosure, the rhenium metal alloy near-net medical device, blank, rod, tube, etc., after being formed into the desired medical device, can be cleaned, polished, sterilized, nitrided, etc., for final processing of the medical device. In one non-limiting embodiment of the present disclosure, the medical device is electropolished. In one non-limiting aspect of this embodiment, the medical device is cleaned before being exposed to the polishing solution, although this is not required. The cleaning process (when in use) can be performed by a variety of techniques, such as, but not limited to, 1) using a solvent and wiping the medical device with a Kimwipe or other suitable towel, and / or 2) by at least partially dipping or immersing the medical device in a solvent and then ultrasonically cleaning the medical device. As can be appreciated, the medical device can be cleaned in other or additional ways.

[0072] The use of rhenium metal alloys to form all or part of a medical device provides several advantages over medical devices formed from other materials, including, but not limited to:

[0073] · Because rhenium metal alloys have higher strength and / or hardness compared to stainless steel, chromium-cobalt alloys, or titanium alloys, less rhenium metal alloys can be used in a medical device to achieve similar strength compared to medical devices formed from different metals. Thus, by using rhenium metal alloys, the resulting medical device can be made smaller and less bulky without sacrificing the strength and durability of the medical device. The medical device can also have a smaller profile, allowing it to be inserted into smaller areas, openings, and / or passageways. Thinner struts of rhenium metal alloys for forming frames or other portions of medical devices can be used to form frames or other portions of medical devices that have strength that would require thicker struts or other structures of the medical device when formed from stainless steel, chromium-cobalt alloys, or titanium alloys.

[0074] The increased strength of rhenium metal alloys also increases the radial strength of medical devices. For example, the wall thickness of a medical device can be thinner and achieve similar or improved radial strength compared to thicker walled medical devices made from stainless steels, cobalt-chromium alloys, or titanium alloys.

[0075] Rhenium metal alloys provide improved stress-strain, flexural, elongation and / or flexibility properties of medical devices compared to stainless steels or chromium-cobalt alloys, thereby increasing the lifespan of the medical device. For example, the medical device may be used in areas where the medical device is to be repeatedly bent. The improved physical properties of the medical device due to the rhenium metal alloys increase the fracture resistance of the medical device in such frequent bending environments. These improved physical properties are attributable, at least in part, to the composition of the rhenium metal alloy, the grain size of the rhenium metal alloy, the carbon, oxygen and nitrogen content of the rhenium metal alloy, and / or the carbon / oxygen ratio of the rhenium metal alloy.

[0076] Rhenium metal alloys reduce the degree of recoil during compression and / or expansion of medical devices compared to stainless steels, chromium-cobalt alloys, or titanium alloys. Medical devices formed with rhenium metal alloys better maintain their compressed shape and / or better maintain their expanded shape after expansion due to the use of rhenium metal alloys. Thus, when the medical device is compressed and is to be mounted on a delivery device, the medical device better maintains its smaller profile during insertion of the medical device into the body passageway. Also, the medical device better maintains its expanded profile after expansion, promoting the success of the medical device in the treatment area.

[0077] The use of rhenium metal alloys in medical devices allows the medical device to better conform to irregularly shaped body passages when expanded within the body passages compared to medical devices formed from stainless steels, chromium-cobalt alloys, or titanium alloys.

[0078] Rhenium metal alloys have improved radiopacity compared to standard materials such as stainless steel or cobalt-chromium alloys, thereby reducing or eliminating the need for marker materials in medical devices. For example, rhenium metal alloys are at least about 10-20% more radiopaque than stainless steel or cobalt-chromium alloys.

[0079] Rhenium metal alloys exhibit improved fatigue ductility when subjected to cold working compared to the cold working of stainless steels, chromium-cobalt alloys, and titanium alloys.

[0080] Rhenium metal alloys offer improved durability compared to stainless steels, chromium-cobalt alloys, and titanium alloys.

[0081] Rhenium metal alloys have improved hydrophilicity compared to stainless steels, chromium-cobalt alloys, and titanium alloys.

[0082] Rhenium metal alloys reduce ion release in body passageways compared to stainless steels, chromium-cobalt alloys or titanium alloys.

[0083] Rhenium metal alloys are less irritating to the body compared to stainless steel, cobalt-chromium alloys, and titanium alloys, which can reduce inflammation, speed up healing, and increase the success rate of medical devices. When a medical device expands within a passageway in the body, some minor damage may occur inside the passageway. When the body begins to heal such minor damage, the body will have less adverse effects on the presence of rhenium metal alloys compared to other metals such as stainless steel, cobalt-chromium alloys, and titanium alloys.

[0084] Medical devices including expandable metal frames formed at least in part from rhenium metal alloys exhibit reduced recoil, improved bending compliance, and improved radial strength compared to expandable frames formed from stainless steel, cobalt-chromium alloys, and TiAlV alloys, which provide the following non-limiting advantages over expandable frames formed from stainless steel, cobalt-chromium alloys, or TiAlV alloys:1) formation of a frame for a medical device with thinner posts, struts and / or strut joints, resulting in i) safer vascular access when inserting the medical device through a body passageway to the treatment area, and / or ii) reduced risk of bleeding and / or damage to the body passageway and / or treatment area when the medical device is delivered to the treatment area and / or expanded in the treatment area; 2) easier delivery of the medical device to the treatment area, resulting in i) reduced trauma to the body passageway (e.g., blood vessels, aortic arch trauma, etc.) during insertion and / or expansion of the medical device in the treatment area, and / or ii) reduced risk of neurological complications - stroke; 3) less recoil, resulting in i) reduced compression characteristic size, ii) improved conformability of the expanded medical device in the treatment area after expansion in the treatment area; iii) increased radial strength of the frame of the medical device after expansion in the treatment area; iv) compression cycles required to compress the medical device onto a balloon catheter or other type of delivery device. v) a reduced incidence of damage to components of the medical device (e.g., struts, posts, strut joints and / or other components of the expandable frame, leaflets, skirts, coatings, etc.) during compression, expansion and manipulation of the medical device; vi) an increased effective orifice area (EOA) of the medical device after expansion of the medical device; vi) a reduced pulmonary valve regurgitation (PVR) after expansion of the medical device in the treatment area; and / or vii) only one expansion cycle of the balloon on the balloon catheter or other expansion mechanism is required to fully expand the medical device; and / or 4) creating a medical device with superior material biological properties to i) improve tissue adhesion and / or growth on or around the medical device; ii) reduce adverse tissue reaction from the medical device; iii) reduce toxicity of the medical device; iv) potentially reduce intravalvular thrombosis during the life of the medical device; and / or v) reduce the incidence of infection during the life of the medical device.

[0085] Medical devices such as expandable medical devices (e.g., expandable heart valves, stents, etc.) comprising rhenium metal alloys according to the present disclosure overcome several unmet needs that exist for expandable medical devices formed of cobalt-chromium alloys, TiAlV alloys, and stainless steels. Such unmet needs addressed by medical devices according to the present disclosure include: 1) reducing the incidence of fatal bleeding during treatment because a large hole does not have to be created in a large artery or other vessel when a compressed medical device is initially inserted into an atrial or other vessel; 2) creating medical devices (e.g., stents, prosthetic heart valves, etc.) that are smaller and have reduced compressibility than medical devices made from cobalt-chromium alloys, TiAlV alloys, and stainless steels, thereby allowing medical devices to be delivered and implanted into or through abnormally shaped heart valves or abnormally shaped arterial vessels caused by calcification in the heart valves and / or calcification and / or plaque in the arterial vessels; and 3) reducing the risk of injury to the implanted medical device as the medical device is expanded within the treatment area by using a frame made from a rhenium metal alloy that better follows the shape of the abnormally shaped heart valve orifice during expansion of the prosthetic heart valve compared to prior art prosthetic heart valves made from cobalt-chromium alloys, TiAlV alloys, and stainless steels. the incidence of paravalvular leaks and / or other types of leaks around the medical device, thereby reducing the incidence of stroke and / or increasing the success rate of the implanted medical device; 4) improving the radial strength of the expanded struts, posts and / or strut joints within the expandable frame and the strength of the expandable frame itself after expansion of the medical device; 5) reducing the amount of recoil of the expandable frame during compression and / or expansion of the expandable frame of the medical device; 6) allowing the use of medical devices in hearts with permanent pacemakers; 7) reducing the incidence of minor strokes during insertion and manipulation of the medical device in the treatment area; 8) reducing the incidence of coronary ostium injury; 9) improving shortening; 10) reducing further aortic valve calcification and / or endovascular calcification after implantation of the medical device; 11) improving the radial strength of the expanded struts, posts and / or strut joints within the expandable frame and the strength of the expandable frame itself after expansion of the medical device; 12) improving the radial strength of the expanded struts, posts and / or strut joints within the expandable frame and the strength of the expandable frame itself after expansion of the medical device; 13) improving the radial strength of the expanded struts, posts and / or strut joints within the expandable frame and the strength of the expandable frame itself after expansion of the medical device; 14) reducing the radial strength of the expanded struts, posts and / or strut joints within the expandable frame and the strength of the expandable frame itself after expansion of the medical device; 15) reducing the radial strength of the expanded struts, posts and / or strut joints within the expandable frame12) reducing the need for multiple compression cycles, 12) reducing the incidence of frame / stent fracture during compression and / or expansion of the medical device, 13) reducing the incidence of biofilm endocarditis following implantation of the medical device, 14) reducing allergic reactions to the medical device following implantation of the medical device, 15) improving the hydrophilicity of the medical device to improve tissue growth on and / or around the implanted medical device, 16) reducing the magnetic susceptibility of the medical device, 17) reducing toxicity of the medical device, 18) reducing the amount of metal ions released from the medical device, and / or 19) increasing the lifespan of the leaflets and / or stent / frame and / or other components of the medical device following insertion of the medical device.

[0086] One non-limiting object of the present disclosure is to provide a rhenium metal alloy according to the present disclosure that can be used to partially or completely form a medical device.

[0087] Another and / or alternative non-limiting object of the present disclosure is to provide medical devices formed partially or completely from the rhenium metal alloys of the present disclosure, which improve the success of procedures.

[0088] Another and / or alternative non-limiting object of the present disclosure is to provide methods and processes for forming rhenium metal alloys in accordance with the present disclosure that reduce or prevent the formation of microcracks during processing of the rhenium metal alloy.

[0089] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device formed partially or completely of a rhenium metal alloy in accordance with the present disclosure, the medical device having improved physical properties.

[0090] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device formed at least in part of a rhenium metal alloy according to the present disclosure, the medical device having increased strength and / or hardness.

[0091] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising at least in part a rhenium metal alloy according to the present disclosure, which allows the medical device to be formed using less material compared to conventional medical devices without sacrificing the strength of the medical device.

[0092] Another and / or alternative non-limiting object of the present disclosure is to provide methods and processes for forming rhenium metal alloys in accordance with the present disclosure to reduce or prevent the formation of microcracks during processing of the rhenium metal alloys that occur when the rhenium metal alloys are processed into medical devices.

[0093] Another and / or alternative non-limiting object of the present disclosure is to provide methods and processes for forming rhenium metal alloys in accordance with the present disclosure that reduce or prevent crack propagation and / or fatigue failure of the rhenium metal alloys.

[0094] The present invention provides a medical device comprising a rhenium metal alloy having a nitriding treatment that forms a nitride layer on an outer surface of the rhenium metal alloy.

[0095] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device including a rhenium metal alloy, where the refractory alloy has been subjected to a swaging process.

[0096] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the refractory alloy having been subjected to a cold working process.

[0097] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy having increased strength and / or hardness as compared to stainless steels, chromium-cobalt alloys, or titanium alloys.

[0098] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, whereby a reduced amount of rhenium metal alloy is required to achieve similar strength as compared to a medical device formed of a different metal.

[0099] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the medical device having a smaller compressed profile as compared to a medical device formed of a different metal.

[0100] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy that has a thinner wall and yet achieves similar or improved radial strength compared to thicker walled medical devices formed from stainless steel, chromium-cobalt alloys, or titanium alloys.

[0101] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the medical device having improved stress-strain, bending, elongation and / or flexibility properties as compared to medical devices formed from stainless steel, titanium steel or chromium-cobalt alloys.

[0102] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the medical device having an extended life span as compared to medical devices formed from stainless steel, titanium steel, or chromium-cobalt alloys.

[0103] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, which exhibits a reduced degree of recoil during compression and / or expansion of the medical device as compared to stainless steel, chromium-cobalt alloys, or titanium alloys.

[0104] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy that conforms better to irregularly shaped body passages when expanded within the body passage as compared to medical devices formed of stainless steel, chromium-cobalt alloys, or titanium alloys.

[0105] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the medical device having improved fatigue ductility when subjected to cold working as compared to cold working of stainless steels, chromium-cobalt alloys, or titanium alloys.

[0106] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the medical device having improved durability as compared to stainless steel, chromium-cobalt alloys, or titanium alloys.

[0107] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the medical device having improved hydrophilicity as compared to stainless steel, chromium-cobalt alloys, or titanium alloys.

[0108] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the medical device having reduced ion release within a bodily passageway as compared to stainless steel, chromium-cobalt alloys, or titanium alloys.

[0109] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, which is less irritating to the body compared to stainless steel, cobalt-chromium alloys, and titanium alloys, resulting in less inflammation, faster healing, and improved success of the medical device.

[0110] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the rhenium metal alloy comprising rhenium, molybdenum, and one or more alloying metals selected from the group consisting of bismuth, chromium, copper, hafnium, iridium, manganese, niobium, osmium, rhodium, ruthenium, tantalum, technetium, titanium, tungsten, vanadium, yttrium, and zirconium.

[0111] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy comprising rhenium, molybdenum, and one or more alloying metals selected from the group consisting of bismuth, chromium, copper, hafnium, iridium, manganese, niobium, osmium, rhodium, ruthenium, tantalum, technetium, titanium, tungsten, vanadium, yttrium, and zirconium, wherein the combined weight percentage of rhenium and alloying metals in said rhenium metal alloy is equal to or greater than the weight percentage of molybdenum in the rhenium metal alloy.

[0112] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the rhenium metal alloy comprising rhenium, molybdenum and one or more alloying metals, and which is at least 10% and less than 60% by weight, wherein the weight percentage of rhenium in the rhenium metal alloy is 35-60% by weight, the total weight percentage of the alloying metals is 5-45% by weight of the rhenium metal alloy, and the total weight percentage of rhenium and alloying metals in said rhenium metal alloy is equal to or greater than the weight percentage of molybdenum in the rhenium metal alloy.

[0113] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the rhenium metal alloy comprising rhenium, molybdenum and one or more alloying metals, wherein the weight percentage of rhenium in the rhenium metal alloy is greater than the combined weight percentage of the alloying metals.

[0114] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the rhenium metal alloy comprising rhenium, molybdenum and one or more alloying metals, wherein the combined weight percentage of rhenium, molybdenum and the one or more alloying metals in the rhenium metal alloy is at least 99.9 weight percent.

[0115] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, where the rhenium metal alloy comprises chromium.

[0116] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the rhenium metal alloy comprising chromium and one or more metals selected from the group consisting of bismuth, zirconium, iridium, niobium, tantalum, titanium, and yttrium.

[0117] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the rhenium metal alloy comprising rhenium, molybdenum, and one or more alloying metals, the one or more alloying agents comprising chromium and one metal selected from the group consisting of bismuth, zirconium, iridium, niobium, tantalum, titanium, and yttrium, wherein the atomic ratio of chromium to the atomic ratio of the one or more metals selected from the group consisting of zirconium, niobium, and tantalum is 0.4:1 to 2.5:1 (and all values ​​and ranges therebetween).

[0118] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the rhenium metal alloy comprising rhenium, molybdenum and one or more alloying metals, the one or more alloying agents comprising chromium and one or more metals selected from the group consisting of zirconium, niobium and tantalum.

[0119] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the rhenium metal alloy comprising rhenium, molybdenum, a first metal selected from the group consisting of bismuth, chromium, iridium, niobium, tantalum, titanium, yttrium, and zirconium, and a second metal selected from the group consisting of bismuth, chromium, iridium, niobium, tantalum, titanium, yttrium, and zirconium, wherein the first metal and the second metal are different.

[0120] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy comprising rhenium, molybdenum, a first metal selected from the group consisting of bismuth, chromium, iridium, niobium, tantalum, titanium, yttrium, and zirconium, and a second metal selected from the group consisting of bismuth, chromium, iridium, niobium, tantalum, titanium, yttrium, and zirconium, wherein the first metal and the second metal are distinct and the atomic ratio of the first metal to the second metal is 0.4:1 to 2.5:1 (and all values ​​and ranges therebetween).

[0121] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the rhenium metal alloy comprising rhenium, molybdenum, a first metal selected from the group consisting of chromium, niobium, tantalum, and zirconium, and a second metal selected from the group consisting of chromium, niobium, tantalum, and zirconium, wherein the atomic ratio of the first metal to the second metal is 0.4:1 to 2.5:1 (and all values ​​and ranges therebetween).

[0122] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the rhenium metal alloy comprising rhenium, molybdenum and one or more alloying metals, the rhenium metal alloy containing less than 0.1% by weight of metals and impurities.

[0123] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the rhenium metal alloy comprising rhenium, molybdenum and one or more alloying metals, the rhenium metal alloy having controlled amounts of nitrogen, oxygen and carbon to reduce microcracking in the rhenium metal alloy, the nitrogen content in the rhenium metal alloy being less than the combined oxygen and carbon content in the rhenium metal alloy, the rhenium metal alloy having an atomic ratio of oxygen to nitrogen of at least about 1.2:1, and the rhenium metal alloy having an atomic ratio of carbon to nitrogen of at least about 2:1.

[0124] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the rhenium metal alloy comprising rhenium, molybdenum and one or more alloying metals, and at least one region of the medical device comprising at least one biological agent.

[0125] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the rhenium metal alloy comprising rhenium, molybdenum and one or more alloying metals, wherein at least one region of the medical device comprises at least one polymer.

[0126] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the rhenium metal alloy comprising rhenium, molybdenum and one or more alloying metals, at least one region of the medical device comprising at least one polymer, the at least one polymer at least partially coating, encapsulating or a combination thereof at least one biological agent.

[0127] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the rhenium metal alloy comprising rhenium, molybdenum and one or more alloying metals, and at least one region of the medical device comprising at least one microstructure on an outer surface of the medical device.

[0128] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the rhenium metal alloy comprising rhenium, molybdenum and one or more alloying metals, at least one region of the medical device comprising at least one microstructure on an outer surface of the medical device, the at least one microstructure being at least partially formed from, comprising, or composed of a material consisting of a polymer, an agent, or combinations thereof.

[0129] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the rhenium metal alloy comprising rhenium, molybdenum and one or more alloying metals, the medical device comprising an expandable frame.

[0130] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the rhenium metal alloy comprising rhenium, molybdenum and one or more alloying metals, the medical device comprising an expandable frame, the expandable frame comprising a plurality of struts.

[0131] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the rhenium metal alloy comprising rhenium, molybdenum and one or more alloying metals, the medical device including an expandable frame, the expandable frame configured to be compressed to a compressed state such that a maximum outer diameter of the expandable frame when in the compressed state is less than a maximum outer diameter of the expandable frame when fully expanded to an expanded state.

[0132] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the rhenium metal alloy comprising rhenium, molybdenum and one or more alloying metals, the medical device including an expandable frame, the expandable frame having a recoil of less than 5% after undergoing a first compression process.

[0133] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the rhenium metal alloy comprising rhenium, molybdenum and one or more alloying metals, the medical device including an expandable frame, the expandable frame having a recoil of less than 5% after being expanded from a compressed state to an expanded state.

[0134] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the rhenium metal alloy comprising rhenium, molybdenum and one or more alloying metals, wherein the rhenium metal alloy is hydrophilic, and the contact angle of a water droplet on a surface of the rhenium metal alloy is 25 to 45° (and all values ​​and ranges therebetween).

[0135] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the rhenium metal alloy comprising rhenium, molybdenum and one or more alloying metals, the rhenium metal alloy having a maximum ion release of a major component of the rhenium metal alloy of 0.5 μg / cm per day when inserted or implanted on or within a patient's body. 2 and a major component of the rhenium alloy is a metal in the rhenium alloy that constitutes at least 2% by weight of the rhenium metal alloy.

[0136] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the rhenium metal alloy comprising rhenium, molybdenum and one or more alloying metals, wherein the rhenium metal alloy exhibits an absolute increase in ion release per dose of rhenium metal alloy in tissue surrounding the medical device within 50 days of being inserted or implanted on or within a patient's body.

[0137] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the rhenium metal alloy comprising rhenium, molybdenum and one or more alloying metals, wherein the medical device is an expandable stent or an expandable prosthetic heart valve.

[0138] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the rhenium metal alloy comprising rhenium, molybdenum and one or more alloying metals, the one or more alloying metals being selected from the group consisting of bismuth, chromium, copper, hafnium, iridium, manganese, niobium, osmium, rhodium, ruthenium, tantalum, technetium, titanium, tungsten, vanadium, yttrium and zirconium, and wherein the combined weight percentage of rhenium and the alloying metals in the rhenium metal alloy is less than or equal to 1000 ppm by weight. the weight percentage of rhenium in the rhenium metal alloy is at least 10 wt.% and less than 60 wt.%, the weight percentage of rhenium in the rhenium metal alloy is 35-60 wt.%, the total weight percentage of the alloying metals is 5-45 wt.% of the rhenium metal alloy, the weight percentage of rhenium in the rhenium metal alloy is greater than the total weight percentage of the alloying metals, and the total weight percentage of rhenium, molybdenum and one or more alloying metals in the rhenium metal alloy is at least 99.9 wt.%.

[0139] Another and / or alternative non-limiting object of the present disclosure is to provide a medical device comprising a rhenium metal alloy, the rhenium metal alloy comprising rhenium, molybdenum and one or more alloying metals, the rhenium metal alloy having a maximum ion release of a major component of the rhenium metal alloy of 0.5 μg / cm per day when inserted or implanted on or within a patient's body. 2 and a major component of the rhenium alloy is a metal in the rhenium alloy that constitutes at least 2% by weight of the rhenium metal alloy.

[0140] These and other advantages will become apparent to those of ordinary skill in the art upon reading this description and what follows.

[0141] For clarity, specific terminology is used in the following description, but these terms are intended to refer only to the particular structures of the embodiments selected for illustration in the drawings, and are not intended to define or limit the scope of the present disclosure. In the drawings and the following description, it is understood that like number designations refer to components of similar function.

[0142] The singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0143] The term "comprising" as used in the specification and claims can include "consisting of" and "consisting essentially of" embodiments, and the terms "comprising," "including," "having," "having," "can," "having," and variations thereof as used herein are intended to be open-ended transitional phrases, terms, or words that require the presence of the specified components / steps and permit the presence of other components / steps. However, such descriptions should also be construed as describing the composition or process as "consisting of" and "consisting essentially of" the recited components / steps, thereby permitting the presence of only the specified components / steps, along with any unavoidable impurities that may result, and excluding other components / steps.

[0144] Numerical values ​​in the specification and claims of this application should be understood to include the same numerical values ​​when converted to the same significant figures, and numerical values ​​that differ from the stated numerical values ​​within less than experimental error of conventional measuring techniques of the type described in this application to determine the values.

[0145] All ranges disclosed herein are inclusive of the recited endpoints and are independently combinable (e.g., the range "from 2 grams to 10 grams" includes the endpoints, 2 grams and 10 grams, and all intermediate values).

[0146] The terms "about" and "approximately" can be used to include any numerical value that can vary without changing the basic function of its value. When used in conjunction with a range, "about" and "approximately" also disclose the range defined by the absolute values ​​of the two endpoints, for example, "about 2 to about 4" also discloses the range "from 2 to 4." In general, the terms "about" and "approximately" may refer to plus or minus 10% of the indicated numerical value.

[0147] Unless expressly stated otherwise, elemental percentages should be assumed to be percentages by weight of the stated element.

[0148] In one non-limiting aspect of the present disclosure, a rhenium metal alloy is provided comprising rhenium, molybdenum, and one or more alloying metals selected from the group consisting of bismuth, chromium, copper, hafnium, iridium, manganese, niobium, osmium, rhodium, ruthenium, tantalum, technetium, titanium, tungsten, vanadium, yttrium, and zirconium.

[0149] In another non-limiting aspect of the present disclosure, a rhenium metal alloy is provided comprising rhenium, molybdenum, and one or more alloying metals, wherein the combined weight percentage of rhenium and the alloying metals in the rhenium metal alloy is greater than or equal to the weight percentage of molybdenum in the rhenium metal alloy.

[0150] In another non-limiting aspect of the present disclosure, a rhenium metal alloy is provided comprising rhenium, molybdenum and one or more alloying metals, wherein the weight percentage of molybdenum in the rhenium metal alloy is at least 10 weight percent and less than 60 weight percent, the weight percentage of rhenium in the rhenium metal alloy is between 35 and 60 weight percent, and the total weight percentage of the alloying metals is between 5 and 45 weight percent of the rhenium metal alloy.

[0151] In another non-limiting aspect of the present disclosure, a rhenium metal alloy is provided that includes rhenium, molybdenum, and one or more alloying metals, wherein the weight percentage of rhenium in the rhenium metal alloy is greater than the combined weight percentage of the alloying metals.

[0152] In another non-limiting aspect of the present disclosure, a rhenium metal alloy is provided comprising rhenium, molybdenum and one or more alloying metals, wherein the combined weight percentage of rhenium, molybdenum and the one or more alloying metals in the rhenium metal alloy is at least 99.9 weight percent.

[0153] In another non-limiting aspect of the present disclosure, a rhenium metal alloy is provided comprising rhenium, molybdenum and one or more alloying metals, the alloying metal comprising chromium.

[0154] In another non-limiting aspect of the present disclosure, a rhenium metal alloy is provided comprising rhenium, molybdenum and one or more alloying metals, the alloying metals comprising chromium and one metal selected from the group consisting of bismuth, zirconium, iridium, niobium, tantalum, titanium and yttrium.

[0155] In another non-limiting aspect of the present disclosure, a rhenium metal alloy is provided comprising rhenium, molybdenum, and one or more alloying metals, wherein the atomic ratio of chromium to the atomic ratio of one or more metals selected from the group consisting of bismuth, zirconium, iridium, niobium, tantalum, titanium, and yttrium is between 0.4:1 and 2.5:1.

[0156] In another non-limiting aspect of the present disclosure, a rhenium metal alloy is provided comprising rhenium, molybdenum and one or more alloying metals, the alloying metals comprising chromium and one or more metals selected from the group consisting of zirconium, niobium and tantalum.

[0157] In another non-limiting aspect of the present disclosure, a rhenium metal alloy is provided comprising rhenium, molybdenum, and one or more alloying metals, wherein the atomic ratio of chromium to the atomic ratio of the one or more metals selected from the group consisting of zirconium, niobium, and tantalum is between 0.4:1 and 2.5:1.

[0158] In another non-limiting aspect of the present disclosure, there is provided a rhenium metal alloy comprising rhenium, molybdenum, and one or more alloying metals, the alloying metals comprising a first metal selected from the group consisting of bismuth, chromium, iridium, niobium, tantalum, titanium, yttrium, and zirconium, and a second metal selected from the group consisting of bismuth, chromium, iridium, niobium, tantalum, titanium, yttrium, and zirconium, wherein the first metal and the second metal are distinct and the atomic ratio of the first metal to the second metal is between 0.4:1 and 2.5:1.

[0159] In another non-limiting aspect of the present disclosure, a rhenium metal alloy is provided comprising rhenium, molybdenum and one or more alloying metals, the alloying metals comprising a first metal selected from the group consisting of chromium, niobium, tantalum and zirconium, and a second metal selected from the group consisting of chromium, niobium, tantalum and zirconium, the first metal and the second metal being distinct and the atomic ratio of the first metal to the second metal is between 0.4:1 and 2.5:1.

[0160] In another non-limiting aspect of the present disclosure, a rhenium metal alloy is provided comprising rhenium, molybdenum and one or more alloying metals, the rhenium metal alloy containing less than 0.1% by weight of metals and impurities.

[0161] In another non-limiting aspect of the present disclosure, a rhenium metal alloy is provided comprising rhenium, molybdenum and one or more alloying metals, the atomic ratio of Re being between 0.8:1 and 1.25:1 relative to the total content of the alloying metals.

[0162] In another non-limiting object of the present disclosure, there is provided a rhenium metal alloy comprising rhenium, molybdenum and one or more alloying metals, the rhenium metal alloy having controlled amounts of nitrogen, oxygen and carbon to reduce microcracking in the rhenium metal alloy, the nitrogen content in the rhenium metal alloy being less than the combined oxygen and carbon content in the rhenium metal alloy, the rhenium metal alloy having an oxygen to nitrogen atomic ratio of at least about 1.2:1, and the rhenium metal alloy having a carbon to nitrogen atomic ratio of at least about 2:1.

[0163] In another non-limiting aspect of the present disclosure, a rhenium metal alloy is provided that includes rhenium, molybdenum and one or more alloying metals, the rhenium metal alloy being used to at least partially form a medical device.

[0164] In another non-limiting aspect of the present disclosure, a rhenium metal alloy is provided comprising rhenium, molybdenum and one or more alloying metals, the rhenium metal alloy being used to at least partially form a medical device, at least one region of the medical device comprising at least one biological agent.

[0165] In another non-limiting aspect of the present disclosure, a rhenium metal alloy is provided comprising rhenium, molybdenum and one or more alloying metals, the rhenium metal alloy being used to at least partially form a medical device, at least one region of the medical device comprising at least one polymer.

[0166] In another non-limiting aspect of the present disclosure, there is provided a rhenium metal alloy comprising rhenium, molybdenum and one or more alloying metals, the rhenium metal alloy being used to at least partially form a medical device, at least one region of the medical device comprising at least one polymer, the at least one polymer at least partially coating, encapsulating or a combination thereof at least one biological agent.

[0167] In another non-limiting aspect of the present disclosure, a rhenium metal alloy is provided comprising rhenium, molybdenum and one or more alloying metals, the rhenium metal alloy being used to at least partially form a medical device, and at least one microstructure is disposed on an exterior surface of the medical device, the at least one microstructure optionally being at least partially formed from, including, or composed of a material consisting of a polymer, an agent, or combinations thereof.

[0168] In another non-limiting aspect of the present disclosure, there is provided a rhenium metal alloy comprising rhenium, molybdenum and one or more alloying metals, the rhenium metal alloy being used to at least partially form a medical device, the medical device including an expandable frame formed of the rhenium metal alloy, the expandable frame including a plurality of struts, the expandable frame optionally configured to be compressed to a compressed state such that a maximum outer diameter of the expandable frame when in the compressed state is less than a maximum outer diameter of the expandable frame when fully expanded to an expanded state, the expandable frame being configured to be compressed to a compressed state such that a maximum outer diameter of the expandable frame when in the compressed state is less than a maximum outer diameter of the expandable frame when fully expanded to an expanded state, the expandable frame being configured to be compressed to a compressed state such that a maximum outer diameter of the expandable frame when in the compressed state is less than a maximum outer diameter of the expandable frame when fully expanded to an expanded state, the expandable frame being configured to be compressed to a compressed state such that a maximum outer diameter of the expandable frame when in the compressed state is less than a maximum outer diameter of the expandable frame when fully expanded to an expanded state, the expandable frame being configured to be compressed to a compressed state such that a maximum outer diameter of the expandable frame when in the compressed state is less than a maximum outer diameter of the expandable frame when fully expanded to an expanded state, the expandable frame being configured to be compressed to a compressed state such that a maximum outer diameter of the expandable frame when in the expanded ... the expandable frame optionally has less than 5% recoil (e.g., 0.1 to 4.99 and all values ​​and ranges therebetween) after being subjected to a compression stress, the expandable frame optionally has less than 5% recoil (e.g., 0.1 to 4.99 and all values ​​and ranges therebetween) after being expanded from a compressed state to an expanded state, the rhenium metal alloy optionally has hydrophilicity, whereby a contact angle of a water droplet on a surface of the rhenium metal alloy is 25 to 45° (e.g., 0.1 to 4.99 and all values ​​and ranges therebetween), and the rhenium metal alloy optionally has a hydrophilicity of 0.5 μg / cm per day when inserted or implanted on or within a patient's body. 2 Less than or equal to (for example, 0.001 to 0.5 μg / cm per day) 2 and all values ​​and ranges therebetween), wherein the major component comprises at least 2% by weight of the rhenium metal alloy, and the rhenium metal alloy optionally exhibits an absolute increase in ion release per dose of rhenium metal alloy in tissue surrounding the medical device within 50 days of being inserted or implanted on or within a patient's body.

[0169] In another non-limiting aspect of the present disclosure, there is provided a rhenium metal alloy comprising rhenium, molybdenum and one or more alloying metals, the rhenium metal alloy being used at least in part to form a medical device, the medical device being an expandable stent or an expandable prosthetic heart valve.

[0170] In another non-limiting object of the disclosure, there is provided a rhenium metal alloy comprising rhenium, molybdenum and one or more alloying metals, the rhenium metal alloy being optionally used to at least partially form a medical device, the one or more alloying metals being selected from the group consisting of bismuth, chromium, copper, hafnium, iridium, manganese, niobium, osmium, rhodium, ruthenium, tantalum, technetium, titanium, tungsten, vanadium, yttrium and zirconium, and optionally a combined weight percentage of rhenium and alloying metals in the rhenium metal alloy is equal to or greater than a weight percentage of molybdenum in the rhenium metal alloy, and the weight percentage of molybdenum in the rhenium metal alloy is at least 10. % by weight and less than 60% by weight (and all values ​​and ranges therebetween), the weight percentage of rhenium in the rhenium metal alloy is 35-60% by weight (and all values ​​and ranges therebetween), the total weight percentage of alloying metals is 5-45% by weight of the rhenium metal alloy (and all values ​​and ranges therebetween), the weight percentage of rhenium in the rhenium metal alloy is optionally greater than the total weight percentage of alloying metals, the total weight percentage of rhenium, molybdenum and one or more alloying metals in the rhenium metal alloy is at least 99.9% by weight, and the rhenium metal alloy optionally has a rhenium concentration of 0.5 μg / cm per day when inserted or implanted on or within a patient's body. 2 Less than or equal to (for example, 0.001 to 0.5 μg / cm per day) 2 and all values ​​and ranges therebetween), wherein the major component comprises at least 2 weight percent of the rhenium metal alloy.

[0171] It will be seen that the above objects are effectively accomplished among the objects made clear from the foregoing description. It is also intended that all matters contained in the above description and shown in the accompanying drawings should be interpreted as illustrative and not in a limiting sense, since certain changes may be made in the described structure without departing from the spirit and scope of the present disclosure. The present disclosure has been described with reference to preferred and alternative embodiments. Modifications and changes will become apparent to those skilled in the art upon reading and understanding the detailed description of the disclosure provided herein. The present disclosure is intended to include all such modifications and changes insofar as they fall within the scope of the present disclosure. It is also to be understood that the following claims are intended to cover all of the general and specific features of the disclosure described herein, as well as all statements of the scope of the disclosure that, as a matter of terminology, lie therebetween.

[0172] (Additional Note) (Appendix 1) A rhenium metal alloy comprising rhenium, molybdenum, and one or more alloying metals selected from the group consisting of bismuth, chromium, copper, hafnium, iridium, manganese, niobium, osmium, rhodium, ruthenium, tantalum, technetium, titanium, tungsten, vanadium, yttrium, and zirconium, the combined weight percentage of rhenium and alloying metal in said rhenium metal alloy is equal to or greater than the weight percentage of molybdenum in said rhenium metal alloy; the weight percentage of molybdenum in the rhenium metal alloy is at least 10% and less than 60% by weight; The weight percentage of rhenium in the rhenium metal alloy is 35 to 60% by weight; the total weight percentage of said alloying metals is 5 to 45 weight percent of said rhenium metal alloy; the weight percentage of rhenium in the rhenium metal alloy is greater than the total weight percentage of the alloying metals; the combined weight percentage of the rhenium, the molybdenum and the one or more alloying metals in the rhenium metal alloy is at least 99.9 weight percent; Rhenium metal alloy.

[0173] (Appendix 2) The alloying metal comprises chromium; 2. The rhenium metal alloy of claim 1.

[0174] (Appendix 3) The alloying metal comprises chromium and one or more metals selected from the group consisting of bismuth, zirconium, iridium, niobium, tantalum, titanium, and yttrium; 2. The rhenium metal alloy of claim 1.

[0175] (Appendix 4) The alloying metal comprises chromium and one or more metals selected from the group consisting of bismuth, zirconium, iridium, niobium, tantalum, titanium, and yttrium; 4. A rhenium metal alloy as described in Appendix 2.

[0176] (Appendix 5) the atomic ratio of the chromium to the one or more metals selected from the group consisting of bismuth, zirconium, iridium, niobium, tantalum, titanium and yttrium is 0.4:1 to 2.5:1; 4. A rhenium metal alloy as described in Appendix 3.

[0177] (Appendix 6) the atomic ratio of the chromium to the one or more metals selected from the group consisting of bismuth, zirconium, iridium, niobium, tantalum, titanium and yttrium is 0.4:1 to 2.5:1; 5. The rhenium metal alloy of claim 4.

[0178] (Appendix 7) The alloying metal comprises chromium and one or more metals selected from the group consisting of zirconium, niobium, and tantalum; 2. The rhenium metal alloy of claim 1.

[0179] (Appendix 8) The alloying metal comprises chromium and one or more metals selected from the group consisting of zirconium, niobium, and tantalum; 7. The rhenium metal alloy according to any one of claims 2 to 6.

[0180] (Appendix 9) the atomic ratio of the chromium to the one or more metals selected from the group consisting of zirconium, niobium, and tantalum is 0.4:1 to 2.5:1; 8. The rhenium metal alloy of claim 7.

[0181] (Appendix 10) the atomic ratio of the chromium to the one or more metals selected from the group consisting of zirconium, niobium, and tantalum is 0.4:1 to 2.5:1; 9. The rhenium metal alloy of claim 8.

[0182] (Appendix 11) the alloying metal comprises a first metal selected from the group consisting of bismuth, chromium, iridium, niobium, tantalum, titanium, yttrium, and zirconium, and a second metal selected from the group consisting of bismuth, chromium, iridium, niobium, tantalum, titanium, yttrium, and zirconium; the first metal and the second metal are different; the atomic ratio of the first metal to the second metal is 0.4:1 to 2.5:1; 2. The rhenium metal alloy of claim 1.

[0183] (Appendix 12) the alloying metal comprises a first metal selected from the group consisting of bismuth, chromium, iridium, niobium, tantalum, titanium, yttrium, and zirconium, and a second metal selected from the group consisting of bismuth, chromium, iridium, niobium, tantalum, titanium, yttrium, and zirconium; the first metal and the second metal are different; the atomic ratio of the first metal to the second metal is 0.4:1 to 2.5:1; 11. The rhenium metal alloy according to any one of claims 2 to 10.

[0184] (Appendix 13) the alloying metal comprises a first metal selected from the group consisting of chromium, niobium, tantalum, and zirconium, and a second metal selected from the group consisting of chromium, niobium, tantalum, and zirconium; the first metal and the second metal are different; the atomic ratio of the first metal to the second metal is 0.4:1 to 2.5:1; 2. The rhenium metal alloy of claim 1.

[0185] (Appendix 14) the alloying metal comprises a first metal selected from the group consisting of chromium, niobium, tantalum, and zirconium, and a second metal selected from the group consisting of chromium, niobium, tantalum, and zirconium; the first metal and the second metal are different; the atomic ratio of the first metal to the second metal is 0.4:1 to 2.5:1; 13. The rhenium metal alloy according to any one of claims 2 to 12.

[0186] (Appendix 15) The rhenium metal alloy contains less than 0.1% by weight of metals and impurities. 2. The rhenium metal alloy of claim 1.

[0187] (Appendix 16) The rhenium metal alloy contains less than 0.1% by weight of metals and impurities. 15. The rhenium metal alloy according to any one of claims 2 to 14.

[0188] (Appendix 17) The atomic ratio of rhenium to the total content of the alloying metal is 0.8:1 to 1.25:1; 2. The rhenium metal alloy of claim 1.

[0189] (Appendix 18) The atomic ratio of rhenium to the total content of the alloying metal is 0.8:1 to 1.25:1; 17. The rhenium metal alloy according to any one of claims 2 to 16.

[0190] (Appendix 19) the rhenium metal alloy has controlled amounts of nitrogen, oxygen and carbon to reduce microcracking in the rhenium metal alloy, the nitrogen content in the rhenium metal alloy is less than the combined oxygen and carbon content in the rhenium metal alloy, the rhenium metal alloy has an atomic ratio of oxygen to nitrogen of at least about 1.2:1, and the rhenium metal alloy has an atomic ratio of carbon to nitrogen of at least about 2:1. 2. The rhenium metal alloy of claim 1.

[0191] (Appendix 20) the rhenium metal alloy has controlled amounts of nitrogen, oxygen and carbon to reduce microcracking in the rhenium metal alloy, the nitrogen content in the rhenium metal alloy is less than the combined oxygen and carbon content in the rhenium metal alloy, the rhenium metal alloy has an atomic ratio of oxygen to nitrogen of at least about 1.2:1, and the rhenium metal alloy has an atomic ratio of carbon to nitrogen of at least about 2:1. 19. The rhenium metal alloy according to any one of claims 2 to 18.

[0192] (Appendix 21) 2. A medical device formed at least in part from the rhenium metal alloy of claim 1.

[0193] (Appendix 22) 21. A medical device formed at least in part from the rhenium metal alloy of any one of claims 2-20.

[0194] (Appendix 23) At least one region of the medical device comprises at least one biological agent and / or at least one polymer; 2. A medical device as described in Appendix 21.

[0195] (Appendix 24) At least one region of the medical device comprises at least one biological agent and / or at least one polymer; 2. A medical device as described in Appendix 22.

[0196] (Appendix 25) At least one region of the medical device comprises at least one polymer, the at least one polymer at least partially coating, encapsulating, or a combination thereof, the at least one biological agent; 2. A medical device as described in Appendix 23.

[0197] (Appendix 26) At least one region of the medical device comprises at least one polymer, the at least one polymer at least partially coating, encapsulating, or a combination thereof, the at least one biological agent; 2. A medical device as described in Appendix 24.

[0198] (Appendix 27) 22. The medical device of claim 21, further comprising at least one microstructure on an exterior surface of the medical device.

[0199] (Appendix 28) 27. The medical device of any one of appendices 22-26, further comprising at least one microstructure on an outer surface of the medical device.

[0200] (Appendix 29) The at least one microstructure is at least partially formed from, includes, or is a combination of a material comprising a polymer, an agent, or a combination thereof; 2. A medical device as described in Appendix 27.

[0201] (Appendix 30) The at least one microstructure is at least partially formed from, includes, or is a combination of a material comprising a polymer, an agent, or a combination thereof; 2. A medical device as described in Appendix 28.

[0202] (Appendix 31) the medical device includes an expandable frame formed from a rhenium metal alloy; The expandable frame includes a plurality of struts; the expandable frame is configured to be compressed to a compressed state such that a maximum outer diameter of the expandable frame in a compressed state is less than a maximum outer diameter of the expandable frame when fully expanded to an expanded state; the expandable frame has a recoil of less than 5% after undergoing a first compression process; the expandable frame has a recoil of less than 5% after expansion from the compressed state to the expanded state; The rhenium metal alloy has hydrophilicity such that the contact angle of a water droplet on the surface of the rhenium metal alloy is 25 to 45°; The rhenium metal alloy, when inserted or implanted on or within a patient's body, has a daily dose of 0.5 μg / cm 2 The maximum ion release of the main component of the rhenium metal alloy is as follows: said major component comprising at least 2 weight percent of said rhenium metal alloy; the rhenium metal alloy exhibits an absolute increase in ion release per dose of rhenium metal alloy in tissue surrounding the medical device within 50 days of being inserted or implanted on or within the patient's body; 2. A medical device as described in Appendix 21.

[0203] (Appendix 32) the medical device includes an expandable frame formed of a rhenium metal alloy; The expandable frame includes a plurality of struts; the expandable frame is configured to be compressed to a compressed state such that a maximum outer diameter of the expandable frame in the compressed state is less than a maximum outer diameter of the expandable frame when fully expanded to an expanded state; the expandable frame has a recoil of less than 5% after undergoing a first compression process; the expandable frame has a recoil of less than 5% after expansion from the compressed state to the expanded state; The rhenium metal alloy has hydrophilicity such that the contact angle of a water droplet on the surface of the rhenium metal alloy is 25 to 45°; The rhenium metal alloy, when inserted or implanted on or within a patient's body, has a daily dose of 0.5 μg / cm 2 The maximum ion release of the main component of the rhenium metal alloy is as follows: said major component comprising at least 2 weight percent of said rhenium metal alloy; the rhenium metal alloy exhibits an absolute increase in ion release per dose of rhenium metal alloy in tissue surrounding the medical device within 50 days of being inserted or implanted on or within the body of the patient; 2. A medical device according to any one of claims 22 to 30.

[0204] (Appendix 33) The medical device is an expandable stent or an expandable prosthetic heart valve. 3. A medical device as described in Appendix 31.

[0205] (Appendix 34) The medical device is an expandable stent or an expandable prosthetic heart valve. 33. A medical device as described in Appendix 33.

[0206] (Appendix 35) A rhenium metal alloy comprising rhenium, molybdenum, and one or more alloying metals selected from the group consisting of bismuth, chromium, copper, hafnium, iridium, manganese, niobium, osmium, rhodium, ruthenium, tantalum, technetium, titanium, tungsten, vanadium, yttrium, and zirconium, the combined weight percentage of rhenium and alloying metal in said rhenium metal alloy is equal to or greater than the weight percentage of molybdenum in said rhenium metal alloy; the weight percentage of molybdenum in the rhenium metal alloy is at least 10% and less than 60% by weight; The weight percentage of rhenium in the rhenium metal alloy is 35 to 60% by weight; the total weight percentage of said alloying metals is 5 to 45 weight percent of said rhenium metal alloy; the weight percentage of rhenium in the rhenium metal alloy is greater than the total weight percentage of the alloying metals; the combined weight percentage of the rhenium, molybdenum and one or more alloying metals in the rhenium metal alloy is at least 99.9 weight percent; The rhenium metal alloy, when inserted or implanted on or within a patient's body, has a daily dose of 0.5 μg / cm 2 The maximum ion release of the main component of the rhenium metal alloy is as follows: the major component comprising at least 2% by weight of the rhenium metal alloy; Rhenium metal alloy.

[0207] (Appendix 36) A rhenium metal alloy comprising rhenium, molybdenum, and one or more alloying metals selected from the group consisting of bismuth, chromium, copper, hafnium, iridium, manganese, niobium, osmium, rhodium, ruthenium, tantalum, technetium, titanium, tungsten, vanadium, yttrium, and zirconium, the combined weight percentage of rhenium and alloying metal in said rhenium metal alloy is equal to or greater than the weight percentage of molybdenum in said rhenium metal alloy; the weight percentage of molybdenum in the rhenium metal alloy is at least 10% and less than 60% by weight; The weight percentage of rhenium in the rhenium metal alloy is 35 to 60% by weight; the total weight percentage of said alloying metals is 5 to 45 weight percent of said rhenium metal alloy; the weight percentage of rhenium in the rhenium metal alloy is greater than the total weight percentage of the alloying metals; the combined weight percentage of the rhenium, the molybdenum and the one or more alloying metals in the rhenium metal alloy is at least 99.9 weight percent; The rhenium metal alloy has hydrophilicity such that the contact angle of a water droplet on the surface of the rhenium metal alloy is 25 to 45°; The rhenium metal alloy, when inserted or implanted on or within a patient's body, has a daily dose of 0.5 μg / cm 2 The maximum ion release of the main component of the rhenium metal alloy is as follows: said major component comprising at least 2 weight percent of said rhenium metal alloy; the rhenium metal alloy exhibits an absolute increase in ion release per dose of rhenium metal alloy in tissue surrounding the medical device within 50 days of being inserted or implanted on or within the patient's body; the rhenium metal alloy, when formed into the expandable frame, exhibits less than 5% recoil after the expandable frame is subjected to a first compression process; the rhenium metal alloy, when formed into the expandable frame, exhibits less than 5% recoil after the expandable frame is expanded from a compressed state to an expanded state. Rhenium metal alloy.

Claims

1. A rhenium metal alloy comprising rhenium, molybdenum, and one or more alloying metals selected from the group consisting of bismuth, chromium, copper, hafnium, iridium, manganese, niobium, osmium, rhodium, ruthenium, tantalum, technetium, titanium, tungsten, vanadium, yttrium, and zirconium, the alloying metals include two or more of bismuth, chromium, zirconium, iridium, niobium, tantalum, titanium, and yttrium; the combined weight percentage of rhenium and alloying metals in said rhenium metal alloy is equal to or greater than the weight percentage of molybdenum in said rhenium metal alloy; the weight percentage of molybdenum in said rhenium metal alloy is at least 10 weight percent; The weight percentage of rhenium in the rhenium metal alloy is 35 to 60 weight percent; the total weight percentage of said alloying metals is 5-45% by weight of said rhenium metal alloy; the weight percentage of rhenium in the rhenium metal alloy is greater than the total weight percentage of the alloying metals; the combined weight percentage of the rhenium, the molybdenum and the one or more alloying metals in the rhenium metal alloy is at least 99.9 weight percent; the atomic ratio of said chromium to said one or more metals selected from the group consisting of bismuth, zirconium, iridium, niobium, tantalum, titanium and yttrium is from 0.4:1 to 2.5:1; Rhenium metal alloy.

2. The alloying metal comprises at least 1 weight percent chromium and one or more metals selected from the group consisting of bismuth, zirconium, iridium, niobium, tantalum, titanium and yttrium. The rhenium metal alloy of claim 1.

3. the atomic ratio of said chromium to said one or more metals selected from the group consisting of bismuth, zirconium, iridium, niobium, tantalum, titanium and yttrium is from 0.5:1 to 2:1; The rhenium metal alloy of claim 2.

4. The alloying metal comprises at least 1 wt. % chromium and one or more metals selected from the group consisting of zirconium, niobium, and tantalum. The rhenium metal alloy of claim 1.

5. the atomic ratio of said chromium to said one or more metals selected from the group consisting of zirconium, niobium and tantalum is from 0.4:1 to 2.5:1; The rhenium metal alloy of claim 4.

6. the alloying metals include a first metal selected from the group consisting of bismuth, chromium, iridium, niobium, tantalum, titanium, yttrium, and zirconium, and a second metal selected from the group consisting of bismuth, chromium, iridium, niobium, tantalum, titanium, yttrium, and zirconium; the first metal and the second metal are different; the atomic ratio of said first metal to said second metal is from 0.4:1 to 2.5:1; The rhenium metal alloy of claim 1.

7. the alloying metal comprises a first metal selected from the group consisting of chromium, niobium, tantalum, and zirconium, and a second metal selected from the group consisting of chromium, niobium, tantalum, and zirconium; the first metal and the second metal are different; the atomic ratio of said first metal to said second metal is from 0.4:1 to 2.5:1; The rhenium metal alloy of claim 1.

8. the atomic ratio of rhenium to the total content of said alloying metals is 0.8:1 to 1.25:1; 3. The rhenium metal alloy of claim 1 or 2.

9. 3. A medical device comprising the rhenium metal alloy of claim 1 or 2, the rhenium metal alloy comprises at least 35% by weight rhenium, at least 1% by weight chromium, and one or more of the alloying metals selected from the group consisting of bismuth, molybdenum, niobium, tantalum, vanadium, manganese, zirconium, technetium, ruthenium, rhodium, hafnium, osmium, and iridium; the rhenium metal alloy comprising 0-0.1 wt. % secondary material; The secondary material is selected from the group consisting of: a) metals other than rhenium, bismuth, molybdenum, niobium, tantalum, vanadium, chromium, manganese, zirconium, technetium, ruthenium, rhodium, hafnium, osmium and iridium; b) carbon; c) oxygen; and d) nitrogen. Medical equipment.

10. 3. A medical device comprising the rhenium metal alloy of claim 1 or 2, the rhenium metal alloy comprises at least 35 wt.% rhenium, at least 1 wt.% chromium, and one or more alloying metals selected from the group consisting of bismuth, molybdenum, niobium, tantalum, vanadium, tungsten, yttrium, and zirconium; the rhenium metal alloy comprising 0-0.1 wt. % secondary material; The secondary material is selected from the group consisting of: a) metals other than rhenium, bismuth, molybdenum, chromium, niobium, tantalum, vanadium, tungsten, yttrium and zirconium, b) carbon, c) oxygen, and d) nitrogen. Medical equipment.

11. 3. A medical device comprising the rhenium metal alloy of claim 1 or 2, the medical device is a heart valve including the frame or a stent including a body; the frame or the body is formed at least in part from the rhenium metal alloy; the frame or body is expandable from a compressed state to an expanded state; the rhenium metal alloy comprises at least 35% by weight rhenium, at least 1% by weight chromium, and one or more of the alloying metals selected from the group consisting of bismuth, molybdenum, niobium, tantalum, vanadium, manganese, zirconium, technetium, ruthenium, rhodium, hafnium, osmium, and iridium; the rhenium metal alloy comprising 0-2 weight percent of a secondary material; the secondary material is selected from the group consisting of: a) metals other than rhenium, bismuth, molybdenum, niobium, tantalum, vanadium, chromium, manganese, zirconium, technetium, ruthenium, rhodium, hafnium, osmium and iridium; b) carbon; c) oxygen; and d) nitrogen; The rhenium metal alloy is a) the rhenium metal alloy has hydrophilicity such that the contact angle of a water droplet on the surface of the rhenium metal alloy is 25 to 45 degrees; b) the rhenium metal alloy is 0.5 μg / cm per day when the frame or body is inserted or implanted on or within the patient's body; 2 having a maximum ion emission of: c) the frame or body formed from the rhenium metal alloy exhibits less than 5% recoil after the frame or body is expanded from an unexpanded state; and d) the frame or body formed from the rhenium metal alloy exhibits less than 5% recoil after the frame or body is subjected to a compression process; having two or more properties selected from the group consisting of Medical equipment.

12. the rhenium metal alloy comprises two or more of the alloying metals selected from the group consisting of molybdenum, bismuth, iridium, niobium, tantalum, titanium, yttrium and zirconium; the rhenium metal alloy comprising 0-0.1 wt. % secondary material; The secondary material is selected from the group consisting of: a) metals other than rhenium, molybdenum, chromium, bismuth, iridium, niobium, tantalum, titanium, yttrium, and zirconium; b) carbon; c) oxygen; and d) nitrogen.

12. The medical device of claim 11.

13. the rhenium metal alloy comprises at least three metals selected from the group consisting of molybdenum, niobium, tantalum and zirconium; the rhenium metal alloy comprising 0-0.1 wt. % secondary material; The secondary material is selected from the group consisting of: a) metals other than rhenium, molybdenum, chromium, niobium, tantalum and zirconium, b) carbon, c) oxygen, and d) nitrogen.

12. The medical device of claim 11.

14. A medical device comprising the metal alloy of claim 1 or 2, the medical device includes an expandable frame formed from the rhenium metal alloy; The expandable frame includes a plurality of struts; the expandable frame is configured to be compressed to a compressed state such that a maximum outer diameter of the expandable frame in a compressed state is less than a maximum outer diameter of the expandable frame when fully expanded to an expanded state; the expandable frame has a recoil of less than 5% after undergoing a first compression process; the expandable frame has a recoil of less than 5% after expansion from the compressed state to the expanded state; The rhenium metal alloy has hydrophilicity such that the contact angle of a water droplet on the surface of the rhenium metal alloy is 25 to 45 degrees; The rhenium metal alloy is at least 0.5 μg / cm per day when the expandable frame is inserted or implanted on or within a patient's body. 2 The maximum ion release of the main component of the rhenium metal alloy is as follows: said major component comprising at least 2 weight percent of said rhenium metal alloy; the rhenium metal alloy exhibits an absolute increase in ion release per dose of rhenium metal alloy in tissue surrounding the medical device within 50 days of being inserted or implanted on or within the patient's body; Medical equipment.

15. The medical device is an expandable stent or an expandable prosthetic heart valve.

15. The medical device of claim 14.